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Abstract 
 
There are a vast array of different molecules which have shown the ability to self-assemble in 
solvent to form a range of nanostructures. Micelles are formed by surfactant-like molecules 
with hydrophobic and hydrophilic parts, and β-sheet fibrils are formed by peptide-based 
molecules. This self-assembly is driven through non-covalent interactions of the domains to 
form supramolecular assemblies. Peptide amphiphiles are one of these groups of self-
assembling compounds. They can be purely peptidic (composed of hydrophobic and 
hydrophilic residues), or a combination of amino acids with hydrophobic lipid chains, 
hydrophilic polymers etc. 
The first part of the thesis concerns three different lipopeptides comprised of the same 
peptide sequence attached to differing numbers of palmitoyl lipid chains. The compounds are 
found to form micellar or bilayer structures, with different morphology and secondary 
structure characteristics, which may explain their differing bioactivities. The second part leads 
on from this and investigated the comparison between the self-assembly of another 
lipopeptide and its constituent peptide. The peptide formed twisted tapes, compared with 
fascinating raft-like structures with the lipopeptide, which to our knowledge had not 
previously been seen before with this class of biomolecule. In chapter 4, a dipeptide attached 
to a bulky aromatic fluorophore is explored through its self-assembly, and cytotoxicity and 
cellular uptake. Large twisted nanotapes were observed above an experimentally determined 
aggregation concentration, and the compound was found to be non-toxic and taken up into 
perinuclear regions of cells. Chapter 5 describes the self-assembly properties of an antifungal 
compound, amphotericin B, at concentrations above an experimentally determined 
aggregation point. It was found that it had a time-dependent change in secondary structure 
and formation of a mixture of cylindrical micelles and very long twisting tapes. In chapter 6, 
the self-assembly of another drug, daptomycin, is examined with and without calcium ions. 
Calcium is believed to be necessary for assembly to occur. No differences were observed here 
however, with similar aggregation concentrations and structures formed in both conditions. 
The final chapter consists of a report on the self-assembly properties of three polymer-peptide 
conjugates with hydrophilic central blocks and hydrophobic tyrosine end-caps, as well as 
preliminary experiments into their cytocompatibility when incorporated into alginate-based 
hydrogels. They were shown to form fibrils with different morphologies and β-sheet content, 
and our study shows the effect on self-assembly of midblock length and polymer type.  
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Chapter 1 - Introduction 
 
1.1 Peptides 
Peptides consist of chains of two or more amino acids linked through covalent peptide bonds.  
These polypeptide chains are formed through reaction of the carboxyl group of one amino 
acid residue with the amine group of another. Literature varies in the exact number of 
residues, but a peptide is deemed to become classified as a protein when the number of 
monomers in the chain increases past a threshold of around 50 [1]. Polypeptide chains consist 
of the main body of repeating amino acids, the backbone, and branches consisting of differing 
residues [1]. There are 22 different amino acids found in organisms, with 20 of those split into 
essential and non-essential amino acids. The former includes 9 amino acids which humans are 
unable to synthesise naturally, and so which need to be ingested through diet. The non-
essential amino acids are able to be synthesised by the human body, and the final two which 
do not fit into either category, selenocysteine and pyrrolysine, are produced through unique 
mechanisms [2]. There are also many other amino acids that have been discovered [3], 
however, they are unable to be incorporated into peptide chains. The names of the amino 
acids can be shortened to either one, or three letter abbreviations, to describe the sequence 
of peptides. Their variability in side chains is what differentiates them, and categories can be 
formed based on these side chain differences. These include hydrophobic, hydrophilic, 
aliphatic, aromatic, and based on charge; positive, negative or neutral.  
 
1.1.1 Peptide self-assembly 
Peptides have the ability to self-assemble into nanostructures based on the presence of 
different amino acids, and which order they are in. The primary structure is based on the 
sequence of the amino acids in the chain, which has an effect on the secondary structure, 
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formed from the polar carboxyl and amine groups binding through hydrogen bonds to other 
peptide chains [1]. Tertiary structure is similar to secondary structure in the sense that it is 
from interactions between chains, but differs through inclusion of non-covalent interactions, 
such as van der Waals forces and hydrogen bonding [1]. These self-assembling peptides can be 
used in the field of medicine, such as in drug delivery systems, or they can be harmful, for 
example as amyloid fibrils, a hallmark of Alzheimer’s disease. This self-assembly can be due to 
the hydrophobic/hydrophilic nature of the peptide, as well as the charge of the amino acids. 
The β-sheet is a common secondary structure which arises from peptide self-assembly. It can 
be present in one of two forms, parallel and antiparallel, shown in figure 1. Antiparallel has 
been shown to be the most common form, which is explained through the higher stability 
compared to the parallel form [4]. β-sheets then may further assemble into nanotubes with a 
hollow centre, nanofibrils with a solid core, and tapes, among other structures [5]. 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 Peptide amphiphiles 
Peptide amphiphiles (PAs) are compounds which have both hydrophilic and hydrophobic 
properties as a consequence of the presence of a lipid chain and order and binding of their 
amino acids. Their structure can be broken down into distinct parts, shown in figure 2. The 
first of these is a hydrophobic section, commonly a long alkyl tail. The second is a small chain 
of amino acids which gives rise to hydrogen bonding within the peptide. The third area is 
comprised of charged residues which increase the solubility of the peptide in water. Finally the 
fourth section is hydrophilic in nature and gives the peptide the ability to communicate with 
cells or other peptides and proteins [6, 7].  
Figure 1 β-sheet structure and orientations. Red and blue lines show hydrogen bonding. 
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Similar to other amphiphilic molecules, peptide amphiphiles also aggregate above a certain 
concentration threshold, the critical aggregation concentration (CAC). Fluorescence methods 
can be used to detect this point. Pyrene is a probe which fluoresces when in a hydrophobic 
environment, making it appropriate for use in determining the CAC of a range of amphiphiles 
[8, 9], including peptide amphiphiles [10, 11]. Another similar method is through use of 
Thioflavin T, which is able to detect CAC in amyloid-like structure, or β-sheet forming, peptides 
[12, 13]. The CAC of lipopeptides is also discoverable using this method [14-16]. 8-
Anilinonaphthalene-1-sulfonic acid (ANS) is another compound used as a fluorescing molecular 
probe. One paper lists a number of different types of substance with which it has been used to 
show the CAC of [17], including protein aggregation and fibril formation [18].  
 
1.2.1 Peptide amphiphile self-assembly 
The self-assembly of peptide amphiphiles is driven through interactions of at least three of the 
sections shown in figure 2; interaction between hydrophobic tails, hydrogen bonding between 
the central peptide section, and electrostatic repulsions from the charged amino acids [6]. The 
ultimate structure formed through self-assembly is a balance between these three forces. 
Through molecular simulations, it was shown that a “pure” hydrophobic interaction would 
lead to formation of fine sized micelles, whereas a “pure” hydrogen bonding system would 
Figure 2 The different domains which make up a PA molecule; hydrophobic tail in black, β-
sheet forming segment in red, charged groups in green, and bioactive epitope in blue. 
Adapted from [6]. 
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lead to formation of a broad distribution of β-sheets [19]. In a system with relatively weak 
hydrogen bonding, spherical micelles are the dominant species, with β-sheets interspersed. 
Upon increasing hydrogen bonding, the spherical micelles are destabilised, leading to long 
cylindrical fibres [19]. The importance of amino acids in the peptide chain on self-assembly 
was also investigated [20]. Using a number of different modified PAs, this group found that the 
four amino acids present nearest to the nanofiber core were responsible for the hydrogen 
bond-forming β-sheets. Conversely, the amino acids further away from the core were found to 
be less important in stabilising the structure. If the hydrogen bonding of these four was 
disrupted, so too was the β-sheet formation, instead leading to the formation of spherical 
micelles. This implies that they are the most important amino acids in a self-assembled 
structure.  
Surfactant-like peptides (SLPs) are an example of PA molecules which consist of a hydrophobic 
tail of at least four successive hydrophobic residues, with at least two charged residues 
forming the headgroup [7]. They have the ability to self-assemble due to their amphiphilic 
nature, which, when in aqueous solution, will generally lead to the hydrophobic tails grouping 
on the inside of the structure. This causes the hydrophilic headgroups to face outwards [6]. 
These headgroups often contain the epitope, the section of the peptide which interacts with 
other proteins and cellular components, and so the self-assembly is important for the 
functionality of the peptide [6]. Another structure which can be formed by self-assembly is the 
β-sheet, which is formed through an alternating pattern of hydrophobic and hydrophilic 
residues creating a sheet with one hydrophobic, and one hydrophilic side [21]. Self-assembly 
can lead to the formation of nanotubes, nanovesicles [22], sheets [23], and other structures, 
such as peptide bilayers [7]. In order for the structures to form, which is important in the 
design of PA molecules for therapeutic use, there must be a correct balance of hydrophobicity 
and hydrophilicity. Too much of the former will lead to the peptide precipitating out, whereas 
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too much of the latter will lead to dissolution, neither of which will lead to the formation of a 
nanostructure [23].  
The ability of the molecules to assemble so that the epitopes are presented on the outside of 
the nanostructure, along with the biocompatibility that the hydrophobic tail provides, means 
that PA molecules can be exploited for medical purposes. They can be used as a drug delivery 
system, with the hydrophobic tail providing entry into the cell, and the epitope interacting 
with the target cellular component or protein to form a complex [24]. Their use in wound 
healing has also been proposed due to their ability to form sheets with bioactive epitopes 
presented at the surface [23, 25]. With a size on the nano-scale range, the PA molecules do 
sacrifice some drug delivery capacity compared with liposomes, but gain the ability to cross 
over cell membranes more easily [25]. There are further advantages, which include a lowered 
risk of being cleared from the body, and a higher surface area to volume ratio, giving higher 
solubility. However, smaller particle size has also been shown to result in a shorter circulation 
time, leading to the belief that 10-100 nm is the ideal diameter for drug delivery systems [1, 
25]. 
The hydrophobic tail is vitally important in PAs as it contributes to the amphiphilicity of the 
molecule, thus allowing it to self-assemble. This causes the tails to sequester on the inside of 
the self-assembled structure, thus exposing the hydrophilic section on the outside. This is 
important when designing PAs to be used in a variety of purposes which require interaction 
from the bioactive epitope. The length of the alkyl chain has been found to be important in 
modulating self-assembly, and in the liability of being influenced by environmental factors 
[26]. The Stupp group used a molecule with a peptide sequence CCCCGGGS(PO4)RGD, with 
varying lengths of alkyl chain. (RGD is a tripeptide sequence, arginine-glycine-aspartic acid, 
which is able to mediate cell adhesion through recognition of cell adhesion molecules [27]). It 
was found that upon acidification, the longer alkyl chain molecules, with 10, 16 and 22 
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carbons, formed gels, whereas the smallest, below 6 carbons, did not. The smallest also 
needed high weight percentage in solution in order to form a precipitate, in contrast to the 
larger alkyl length molecules which were able to precipitate even at the lowest weight 
percentage used. The length of the alkyl chain has also been shown to have an effect on the 
thermal stability of structures formed through self-assembly [28, 29]. In these studies, two 
different length monoalkyl chains, C6 and C16, were found to form an α-helical structure in 
water compared with the peptide with no chain attached which had no discernible structure. 
The C16 PA had higher thermal stability than the C6 one, also seen with another 39-residue 
triple-helical model peptide tested. This work leads on from previous research which found 
the same increase in thermal stability with a longer dialkyl chain compared with the peptide 
without it [30].   
The effect on self-assembly of the hydrophobic tail length of A3K, A6K, and A9K was 
investigated [31]. A3K was found to have no cac in this study, and was shown through atomic 
force microscopy (AFM) to form stacked bilayers. A6K and A9K did give cac values, with A6K 
being higher than A9K, and these peptides were found to assemble into long fibres/worm-like-
micelles, and short narrow rods respectively. In contrast, other studies have found A6K in fact 
forms nanotubes above a experimentally determined cac in one study [32], and above a 12 
wt% threshold in another [33].The length of the hydrophobic peptide chain in these peptides 
was investigated for its effect on antibacterial capacity [34]. Using both Gram-negative 
(Escherichia coli) and Gram-positive (Staphylococcus aureus) bacterial strains, A3K was shown 
to give the weakest antibacterial activity, followed by A6K, with A9K giving the highest. The 
mode of antibacterial action has been proposed to be cell permeation, and thus was expected 
that smaller nanostructure objects would more readily pass through the bacterial cell 
membrane. This correlates with the results seen here as the thinner and smaller self-
assembled AnK structures, with the more hydrophobic tails, the higher the observed 
antibacterial efficiency.  
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1.3 Lipopeptides 
Lipopeptides are a type of peptide amphiphile formed of two main parts; a hydrophobic 
alkyl/lipid chain, attached to a hydrophilic peptide section. They are one of the most popular 
biosurfactants (surfactants produced by bacteria, yeast or fungi) which are produced as a 
defence mechanism against other microorganisms [35, 36]. These lipopeptide producers 
include genera of fungi such as Aspergillus, and bacteria including Streptomyces, Pseudomonas 
and Bacillus [37]. Bacillus subtilis is the producer of what is believed to be the most active 
lipopeptide, surfactin [38, 39]. It has been suggested that some of the biological functions of 
surfactin, including its ability to form ionised pores in phospholipid bilayers, are due to it being 
an amphiphile [40]. Other potent lipopeptides include a group called polymyxins, produced by 
Bacillus polymyxa among others, which generally consist of a hydrophobic tail bound to a 
cyclic peptide [41, 42]. Polymyxin B and E (also known as colistin) both possess antibacterial 
activity versus a number of gram-negative bacteria [43]. Their cationic properties allow them 
to bind to the anionic bacterial outer membrane, causing membrane damage and leading to 
cytoplasmic leakage [41].  
Daptomycin, produced by Streptomyces roseosporus, is a cyclic lipopeptide drug used in the 
treatment of life-threatening infections caused by Gram positive bacteria [44, 45]. The 
molecular structure is shown in figure 3. It is usually used when resistance to other drugs is 
seen, such as in methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant 
Enterococci [44, 46]. Interestingly, daptomycin contains a non-natural amino acid, L-
kynurenine, which is responsible for the lipopeptide’s fluorescence properties with an 
emission peak at 460 nm [47, 48]. Daptomycin’s suggested mechanism of action involves 
insertion of its hydrophobic decanoyl chain into the bacterial membrane [46, 48, 49]. This 
causes the outflow of potassium ions from the cell, leading to cell death [50]. There are studies 
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which suggest that this mechanism is calcium ion dependent, and that their presence causes 
oligomerization, with dissociation at the cell membrane [51].  
 
 
 
 
 
 
 
 
 
As well as daptomycin, there are many other cyclic lipopeptides which show antimicrobial 
activity. These include the echinocandins, a group of antifungal compounds which show 
activity mainly against the Candida and Aspergillus species, with a few exceptions [52]. Their 
mechanism of action involves inhibition of β-(1,3)-glucan synthesis, which causes damages to 
the fungal cell walls. There are 3 main echinocandins which have regulatory approval to be 
used in treatment. These are caspofungin, micafungin and anidulafungin, shown in figure 4 
[53]. All of the echinocandins that are licensed or are in development for therapeutic use are 
amphiphilic cyclic hexapeptides with molecular weights of approximately 1200 [52]. The main 
three differ in their attached side chains. Caspofungin has a fatty acid side chain, micafungin 
has a complex aromatic side chain, and anidulafungin has an alkoxytriphenyl side-chain [52].  
Figure 3 Molecular structure of daptomycin. 
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A group of cyclic lipopeptides under the name Iturins have a peptide motif attached via an 
amide bond to a β-amino fatty acid [35]. They include Iturin A, C, D and E, as well as 
bacillomycin D, F and L, bacillopeptin, and mycosubtilin [54]. They have a broad range of 
activity against yeasts and fungi, as well as a small number of bacteria [55]. Their method of 
action involves increasing the permeability of membranes, leading to K+ ion leakage, and 
ultimately cell death [56]. This is through the formation of ion-conducting pores, dependent 
on the characteristics of the target membrane, as well as the peptide motif on the iturin [55]. 
Fengycin is a similar group to Iturin, with a cyclic peptide linked to a β-hydroxy lipid tail. They 
differ through their structures containing unusual amino acids, for example ornithine and allo-
threonine [57]. The fengycin group includes fengycin A and B, and plipastatin A and B, which 
have been shown to give high antifungal activity, specifically against filamentous fungi [58]. 
The kurstakin group comprises the lowest molecular weight lipopeptides, produced by the 
Gram-positive subspecies Bacillus thuringiensis kurstaki HD-1 [35]. They differ through their 
lipid chain, whilst retaining the same amino acid sequence [59]. It has been suggested that the 
kurstakins are pore-forming, but have only limited spectrum of activity [59].  
Amphotericin B, although not classified as a lipopeptide, is another well-characterised 
antifungal drug. Like daptomycin, it is produced by a Streptomyces species, in this case 
Streptomyces nodosus, and has been used against a range of fungal infections for over 50 
years without resistance developing against it, in contrast to many other antifungals [60, 61]. 
One of the main disadvantages of amphotericin use is its high toxicity, leading to side effects 
including nausea, rigors, fever, and hypo/hypertension [62]. Its mechanism of action is 
believed to be through the formation of pores in the cell walls of fungi, with preferential 
selectivity for ergosterol, present in fungal cell membranes but not in those of humans [63]. 
Amphotericin binds in pairwise form with another amphotericin molecule at the hydrophobic 
polyene backbone, forming a dimer. It is suggested that this dimer over time forms into a 
tetramer, and that the toxicity of the drug is due to the dimer form [64, 65].  
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1.3.1 Further uses of lipopeptides 
Lipopeptides also have applications in the cosmetic industry, notably in skincare in anti-wrinkle 
formulations. One of these is C16-KTTKS, also known by the trade name Matrixyl [66, 67]. Many 
of the peptides used in skin care formulations are lipidated, often with palmitoyl chains, 
shown to increase permeability through the outer layer of skin [68, 69].  KTTKS is a 
pentapeptide sequence which has been shown to inhibit collagenases, and lead to an increase 
in extracellular matrix production (ECM) [70]. The latter is thought to be through a synergistic 
effect whereby the presence of KTTKS with transforming growth factor beta-1 (TGF- β1) leads 
to an increase in fibroblast activity, ultimately increasing ECM formation [67]. The Hamley 
group has undertaken considerable research into C16-KTTKS and its self-assembly. They found 
it assembled into incredibly long tape like structures of micron length, with polydisperse width 
on the nanoscale [71]. Due to the presence of other surfactants in formulations of skin-care 
products, model surfactants were also tested for their influence on self-assembly of C16-KTTKS. 
It was found that both sodium dodecyl sulphate (an anionic surfactant) [72], and Pluronic 
copolymer P123 (a non-ionic surfactant) [73] have an effect, changing from nanotapes to 
differing fibril structures. The same group also compared the self-assembly of C16-KTTKS 
against two other cosmetically active PAs, C16-GHK and C16-KT [74]. The latter two were shown 
to form crystal-like aggregates with relatively lower β-sheet content than the C16-KTTKS 
nanotapes. All 3 did however show bilayer structures through SAXS experiments, along with 
similar aggregation concentrations.  
 
1.4 Toll-like receptor agonists 
Lipopeptides have also been developed which act as toll-like receptor (TLR) agonists. Toll-like 
receptors are a class of transmembrane receptors involved in the innate immune system, and 
which make up an important group of pattern recognition receptors (PRRs) [75]. They are 
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composed of an N-terminal ligand recognition domain, with the cytoplasmic signalling section 
at the C-terminal end [76]. They are split between receptors that recognise bacterial and 
fungal-derived components, present on the surface of cells, and microbial and viral-derived 
components, present in intracellular membranes [77]. There are a number of different TLRs, 
numbered 1-13, although 12 and 13 are not found in humans [78]. TLR 1, 2, 4, 5 and 6 are 
found in the plasma membrane and in general are responsive to hydrophobic components, 
whereas TLR 3, 7, 8, 9 and 11 are located in the endosome and are usually responsive to 
hydrophilic residues [79-82]. When ligand binding to TLRs occurs, adaptor molecules are 
recruited in the cytoplasm, forming part of the signal transduction pathway [83]. This activates 
an immune response, releasing cytokines causing inflammation, as well as immune cells such 
as MHC and adhesion molecules [84].  
 
 
 
 
 
 
 
 
 
 
Figure 4 Cellular districution of Toll-like receptors (TLRs). TLRs 1,2,4,5 and 6 are expressed on 
the cell surface, while TLRs 3, 7, 8, 9 and 11 are expressed intracellularly. Adapted from [162]. 
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1.4.1 TLR agonist agents in cancer treatment 
Due to activation of TLRs having such an important role in innate immune response, they have 
become a target for disease treatment. TLR agonists have been investigated for potential use 
in cancer treatment, with some mouse models showing reduced tumour growth, and 
destruction of established tumours when combined with other anti-cancer drugs [85-88]. The 
effect of different TLRs on different cancer types has been reviewed [89]. Here it is shown that 
in some cases, activation of TLRs on one type of cancer can induce cell death, whereas on 
another cancer cell type can induce cell survival, and even proliferation and promotion of 
resistant phenotypes. There are only 3 different TLR agonists that have been approved by the 
FDA as monotherapy treatments of cancer; BCG (Bacillus Calmette-Guerin), MPL 
(monophosphoryl lipid A), and imiquinmod. Probably the most successful of these, BCG, is 
used in the treatment of bladder cancer [90]. It activates both TLR 2 and TLR 4 through the 
mycobacterial component, and also TLR 9 through its bacterial DNA [91, 92]. MPL is part of a 
broader group of lipid A molecules which stimulate TLR 4 and are often used as vaccine 
adjuvants [90]. It contains the lipid part of lipopolysaccharide (LPS), known to illicit a strong 
immune response in animals, but has been shown to be at least 100 times less toxic [93]. It has 
been safely used in vaccines for both hepatitis B, and human papillomavirus (HPV) [94]. 
Imiquimod is a target of TLR 7 and is used in the treatment of superficial basal cell carcinoma, 
but also in a wide range of other diseases including HPV-related warts [90]. Like imiquimod, 
another type of imidazoquinoline called resiquimod has potential to be used as a vaccine 
adjuvant, and in humans has been shown to activate both TLR 7 and 8 [95].  
As previously mentioned, TLR agonists have potential to be used in combination with other 
conventional anti-cancer treatments. They can augment chemotherapy, ionising radiation or 
monoclonal antibodies [90]. Studies have shown that when an agonist of TLR 2 and 4 is added 
alongside chemotherapy, tumour progression is reduced, and survival is prolonged in liver or 
lung metastases [96]. This is through the controlled release of tumour necrosis factor-alpha 
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(TNF-α) which causes easier passage into tumour vessels for anti-cancer drugs. This leads to 
arresting of tumour-related angiogenesis [97]. The TLR agonists also activate a signalling 
pathway which leads to increased expression of inducible nitric oxide synthase (iNOS), helping 
apoptosis in chemotherapy-resistant tumour cells [98]. Alongside the studies into liver and 
lung cancers, TLR agonists have also been shown to work alongside other conventional 
treatments against sarcoma, mammary carcinoma, and lymphoma [99, 100]. Mouse models 
were used to show CpG oligodeoxynucleotides (ODNs), synthetic DNA sequences that have 
immunostimulatory effects, act upon TLR 9 present on dendritic and B cells, enhancing the 
effects of radiotherapy. Further research has shown the same using CpG in initial tests in 
patients with malignant glioma and non-Hodgkin lymphoma [101, 102]. Ultimately, the future 
of TLR agonist use in cancer treatment is believed to be when used in combination with other 
anti-cancer agents, rather than as a singular medication.  
 
1.4.2 TLR agonist agents in non-cancer treatment 
Although cancer is a large target for TLRs used in therapy, TLR agonists may have already 
shown, or have the potential, to be used in a number of other ways. Macrophage-activating 
lipopeptide 2 (MALP-2) was originally isolated from Mycoplasma fermentans, and as its name 
suggests is a potent stimulator of macrophages, as well as monocytes [103]. It binds to TLR 2 
and 6 in epithelial cells, which leads to a signalling cascade causing activation of NF-ϰB [104]. 
In murine models, this has been shown to occur in the lungs and leads to a decrease in 
bacterial burden when used against Streptococcus pneumoniae [105]. There is also a related 
synthetic analog of MALP-2, Pam2Cys, which has been used as a vaccine adjuvant candidate in 
a number of cases [106-108]. A PEGylated version of the compound has been tested without 
the presence of antigen in a mouse model [109]. PEG-Pam2Cys was intranasally introduced to 
the mice, causing an influx of neutrophils and macrophages. This was shown to increase 
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resistance to the influenza A virus, as well as reduce the risk of transmission. Another positive 
from this case was that the compound didn’t completely prevent infection, allowing the 
production of memory T cells, and thus protection against further infection.  
As well as showing potential in cancer treatment, CpG-ODN has also been used against a 
number of different infections. In one case it showed both protective immunity, and was 
curative, against Leishmania major infection in mice [110]. Protection and cure were both also 
found by a different group against herpes simplex virus type 2 (HSV-2) when CpG-ODN was 
given mucosally in mice [111]. Another study found that bacterial DNA containing 
unmethylated CpG motifs gave mice protection against otherwise lethal doses of both 
Francisella tularensis and Listeria monocytogenes [112]. Jiang et al. investigated the efficacy of 
a modified version of CpG-ODN, 1826, against the H1N1 strain of influenza which had caused a 
pandemic in 2009 [113]. Using a mouse model, it was shown that injection of the synthetic 
compound prior to introduction of H1N1 lead to inhibition of virus replication in the lungs, 
reduced lesions, and prevented mortality. Using a combination of another CpG-ODN, and 
Pam2CSK4, a diacylated lipopeptide, a high resistance to a variety of lung infections was found 
when tested synergistically in mice [114]. The combination of the two allowed for activation of 
TLR 2 and 6 (Pam2CSK4) and TLR 9 (CpG-ODN), which showed survival against otherwise lethal 
doses of both Gram positive, Streptococcus pneumoniae, and Gram negative, Pseudomonas 
aeruginosa, infections in mice. In vitro, the combination also showed reduction in bacterial 
cells of Bacillus anthracis.  
 
1.5 Light, temperature and pH effect on PAs 
PAs can be manipulated by altering their local environment, allowing for another level of 
control for their design in different applications. There are a number of factors which can have 
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an effect on the self-assembly of PAs. These include the use of UV light, altering of pH and 
temperature, and the use of enzymes in enzyme-responsive systems. 
One group has been particularly involved in the manipulation of peptides, including using UV 
light [115]. They had already shown that introducing hydrophobic tails to peptides which have 
the ability to form fibrils stabilises the structures and allows them to more easily be 
manipulated [116, 117]. In ref. [115], they investigated the disassembly of peptide aggregate 
fibres through manipulation of hydrophobicity by attaching a UV-sensitive cleavable 
hydrophobic alkyl chain to a hexapeptide. Upon treatment with UV light, the linker was 
cleaved, which led to the dissociation of the fibres. This was determined by CD, which showed 
a transformation from a β-sheet to a random coil. Another example of UV light being used to 
manipulate peptide self-assembly was investigated by another group [118]. Similarly to the 
previous paper, an alkyl chain was used, this time with a UV-sensitive 2-nitrobenzyl group, 
which was linked to the hydrophilic peptide chain RGDS. Light exposure caused a change in 
structure from nanospheres to nanofibers, also causing a transition from a solution to a gel. 
Another paper by the Stupp group used the same 2-nitrobenzyl cleavable linker, this time 
attached to a GV3A3E3 peptide [119]. The effect of light exposure here caused a transformation 
of quadruple helices to single fibres upon cleavage of the photo-sensitive linker. Light-sensitive 
linkers have also been used in cell culturing [120]. In this case, another nitrobenzyl linker was 
used and enabled an RGDS cell adhesion epitope to be removed from the PA upon exposure to 
light, allowing for more control over the spreading of cells. This time however, the self-
assembled nanofiber structures were not transformed, and stayed the same. 
Temperature can also have an effect on the self-assembly and conformation of peptide 
amphiphiles, seen also by past and present members of our group [121-123]. These 
investigations initially centred around C16-KTTKS, which is known to simulate collagen 
production [67]. It was found that at 20oC, a β-sheet structure was present, and upon heating 
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above 55oC, a transformation into a random coil arrangement was seen. This was confirmed 
through CD, which also found that upon cooling back down to 20oC, over time it reassembled 
into a β-sheet [122]. Another peptide, C16-KKFFVLK, underwent the same heating and cooling 
regime and was found to transition from a mixture of helical ribbons and nanotubes to twisted 
tapes above 55oC [123]. Like with the previous PA, the structural change was shown to be 
reversible upon cooling.  
The self-assembly of PAs can also be affected by pH changes. The PA, C16-KTTKS, was also 
investigated at a range of pHs, from pH 2-7 [124]. The PA has applications in skin care as an 
anti-wrinkle formula, and so pHs 4-7 were chosen to cover the range found in skin. It was 
found that at pH 7, tape-like structures are seen, at pH 4 they become twisted right handed 
structures, pH 3 they were flat and tape-like, and at pH 2 spherical micelles were seen. 
Another paper discussed a PA with a C16 alkyl tail, this time with an RGD cell adhesion motif 
attached [26]. It was found that fibres are formed at pH 4 and disassemble at higher pH, and 
that these states are reversible.   
 
1.6 Hydrogels 
Hydrogels are often networks of polymers (natural or synthetic), as well as small molecules, 
which have the ability to absorb large amounts of water or other biological fluids [125, 126]. 
Their networks can be formed from a range of different types, including covalent bonds 
between monomers, cross-links, and intermolecular interactions such as hydrogen bonding 
and van der Waals forces [125]. Hydrogels can be categorised into a range of different types 
based on their characteristics, one of which is their subunits. Homopolymer gels are ones 
which consist of only one monomeric subunit type, copolymers of two or more different types, 
and interpenetrating polymeric networks which are formed of entangling non-covalent bonds 
between two or more different networks [125]. Hydrogels may also be distinguished by their 
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ionic charges as neutral, anionic, cationic, or ampholytic, meaning they carry both a positive 
and negative charge. Finally, their physical architecture may be termed amorphous with 
random chain organisation, semicrystalline with compact ordered chains, or hydrogen-bonded 
giving a 3-dimensional structure to the network [125].  
Environmental factors such as pH, temperature, etc., can have an effect on the structure and 
swelling of hydrogels sensitive to them, making them ideal drug delivery systems due to the 
control over when the drug is released based on these factors [125]. Only hydrogel networks 
which have either acidic or basic units or both are sensitive to changes in pH [125]. When 
these groups are ionised by a change of pH, the network’s swelling force is increased due to 
the development of fixed charges throughout. Temperature-sensitive hydrogels generally have 
increased solubility at lower temperatures that leads to swelling. At higher temperatures, the 
hydrophobicity of the compound increases and this leads to precipitation [125].  
 
1.6.1 Natural and synthetic hydrogels 
Naturally-derived and synthetic polymers differ in many ways when incorporated as hydrogels. 
Biocompatibility is generally higher in natural polymers than synthetic ones, with the latter 
having a higher instance of causing negative bodily responses [127]. This is due to the 
recognition of the naturally-derived materials by the surrounding environment of the body, 
although this may lead to an immune reaction which is a larger concern with protein-based 
polymers. Synthetic polymers however are more likely to be recognised by the body as 
foreign, which can lead to inflammatory responses, problems with clearance of the hydrogel, 
and toxicity [127]. Conversely, due to the body’s recognition of natural polymers, they may be 
more easily cleared through enzymatic or hydrolytic degradation, which is an advantage for 
hydrogels which are only in place for a short-term specified time, although this obviously 
represents a problem for more permanent placements. Synthetic polymers have some 
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advantages over natural ones due to their simplicity of structure, which often makes chemical 
modifications much easier, and also provide a greater control over structure and mass [127].  
The most common naturally-derived polymer in animals is collagen, due to its presence in a 
large number of different human tissues [127]. Collagens are easily degraded and cleared by 
enzymes which recognise them, and they allow a range of cell types to attach. The 
disadvantages of collagen-based hydrogels are that they are expensive, can cause 
immunogenic reactions, and, even when cross-linked with other compounds, can lack strength 
[128]. Gelatin is another common polymer, and closely-resembles collagen in that it is formed 
through the breakage of the collagen’s triple helix, leaving the three separate coils [127]. 
Tissue engineering is one of its main areas of use due to high biocompatibility, the ability to 
easily form a gel, and the ability to control gelation through temperature. Other examples of 
natural polymers used for the production of hydrogels include hyaluronate, fibrin, alginate 
(shown in figure 5), agarose and chitosan, which each have differing advantages and 
disadvantages in tissue engineering [129]. 
 
 
 
 
 
 
 
 
Figure 5 Cross-linking of sodium alginate with calcium ions. 
 20 
 
One of the most commonly investigated synthetic polymers is poly (2-hydroxyethyl 
methacrylate), or poly (HEMA) [127, 130]. The properties of poly (HEMA) hydrogels are 
dependent on what other molecules or compounds they are cross-linked with [127]. Due to 
their inability to be degraded in the environment of the body, a new type incorporating 
dextran into the structure was produced, which was enzyme-degradable through cross-link 
hydrolysis [131]. Other poly (acrylic) synthetic polymers include poly (N-isopropylacrylamide), 
which has the benefit of having a lower critical solution temperature (LCST) of around 32 °C. 
This means that the polymer containing a drug can be injected into the body in a hydrated 
state, and then at body temperature, a volume transition phase occurs which shrinks it down, 
reducing its size dramatically and releasing the drug [127]. However, hydrogels of this polymer 
suffer setbacks commonly seen with synthetic polymers through a lack of degradation of 
cross-links, although, as with poly (HEMA), this can be rectified through incorporation of 
dextran [132], which also solves some of the toxicity issues.  
Another synthetic polymer, poly (ethylene oxide), or PEO, does not suffer from toxicity issues 
in its native form, and still maintains a high biocompatibility [127]. Its poor degradability under 
physiological conditions can be alleviated through addition of degradable units such as esters 
or Ala-Pro-Gly-Leu chains, which also makes such copolymers suitable in tissue engineering 
[133]. Copolymers of PEO, such as triblock copolymers with poly (propylene oxide), or PPO, 
sandwiched between two PEO molecules, also have interesting properties. PEO-PPO-PEO is 
able to form a hydrogel through control of temperature, but without permanent cross-link 
formation [134]. This triblock copolymer again has the issue of lack of degradation however, 
and so copolymers with poly (lactic acid), or PLA, have been developed, with existing proof of 
the safety of PLA [135]. Other synthetic polymers include poly (vinyl alcohol) used as a long-
term structure for cell culturing due to its physiological degradation issues, polyphosphazene, 
and synthetically prepared proteins designed to mimic natural proteins, which have issues due 
to the complexity of their production [127, 128].  
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1.6.2 Further applications of hydrogels 
The use of hydrogels in contact lenses was one of the first biomedical uses due to their 
permeability to oxygen, material properties (being both soft enough as to not irritate the 
eyeball, but strong enough to withstand eye movement), and their surface hydrophilicity 
which enables sustained contact to the eyeball through their wetting ability [136]. This is an 
example of a use of the synthetic polymer, poly (HEMA) [137]. 
As previously mentioned, hydrogels can also be used in the delivery of drugs. Along with the 
factors aforementioned, hydrogels are also suited through their ability to protect the drug 
from environments which would otherwise damage the drug on the way to its designated site, 
such as acidic pH in the stomach and enzyme degradation [138]. They can also be synthesised 
separately from the drug itself, with the drug later added to the self-assembling system [25]. 
The property of hydrogels to absorb large amounts of water allows them to become ideal 
candidates to mimic the environment of tissues, which themselves are heavily hydrated, and 
to be used for the delivery of drugs and in wound healing. The β-sheet structure, which is very 
stable in water, can become the scaffolding which allows cells to attach to and culture on [21, 
139]. Hydrogels provide a three dimensional scaffold for cell culturing, which has both 
advantages and disadvantages over two dimensional monolayer cell culturing. Three 
dimensional cell culturing more accurately mimics the natural environment of cells in tissues, 
influencing spatial organisation, as well as well as interactions with other cells [140, 141]. 
However, two dimensional cultures have easier environmental control, observation of cells, 
measurement and manipulation [140]. A problem associated with normal cell culturing is the 
use of proteases such as trypsin to detach cells from dishes or flasks as they can cause damage 
to the cells. Culturing cells on temperature-responsive hydrogels like poly (N-
isopropylacrylamide) enables them to be detached easily by lowering the temperature [142].  
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1.6.3 Enzyme-responsive hydrogels 
Enzyme-responsive hydrogels change their functionality based on interaction with enzymes 
[143], similar to the temperature, pH etc., sensitive hydrogels mentioned before. These 
hydrogels present a unique concept in medical applications as the targets of the hydrogels for 
medical applications, i.e. humans, require enzymes for all of their physiological processes. The 
major advantages are that due to the specificity of enzymes for substrates, hydrogels can be 
designed to target certain areas before being activated/changed, and their efficiency as a 
catalyst means enzyme-responsive hydrogels can be fast acting [143]. In the design of these 
hydrogels, they must fit within certain criteria. Firstly, there must be an active site on the 
material similar to the substrate with which the enzymes react. There must also be a 
translation of the effect at the active site throughout the entirety of the hydrogel, followed by 
a change in the properties of it [143]. With enzyme-sensitive peptide-based hydrogels, 
naturally they will largely be targeted by proteases, of which there are many. Here, the 
proteases have the potential to either degrade or functionalise the hydrogel [143].  
Enzyme-responsive hydrogels may be used in cell culturing. They can be functionalised with 
peptides, such as the short sequence Arg-Gly-Asp, or RGD [144], which leads to certain cell 
types attaching through integrins [145]. Ile-Lys-Val-Ala-Val (IKVAV) is another peptide 
sequence that can be incorporated into hydrogels in order to signal neuronal cell 
differentiation from stem cell progenitors [146]. Heparin is a biological molecule with one of 
its functions being that it binds to pro-angiogenic growth factors such as vascular endothelial 
growth factor (VEGF) [147, 148]. It was shown to give higher neovascularization when 
incorporated into a hydrogel and inserted into a pocket near a rat cornea [149]. The use of 
these hydrogels in the repairing of tissue damage has also been proposed in the form of an 
injectable scaffold [150]. This idea has led to two different proposed models of action. The first 
is that the cells are allowed to grow in a culture, and then mature on the hydrogel before then 
being implanted into the wound. The second is the hydrogel is implanted into the wound, and 
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the native cells surrounding the structure are allowed to grow and mature onto it, forming the 
tissue. For both strategies, adhesion peptides, such as RGD mentioned before, would need to 
be incorporated into the hydrogel, along with other bioactive molecules such as growth 
factors and matrix metalloproteinases (MMPs) [150]. MMPs are responsible for degrading 
various ECM components, which when normally regulated, is important in development, 
tissue repair etc. [151].  
Enzyme-responsive hydrogels have also been discussed as having potential applications in 
diagnostics [152]. The amount of enzyme activity that is under investigation may be quantified 
through the observation of gel phase conversion from a solid to a gel. This change can be seen 
without the need for expensive specialised equipment, and so represents a cheaper 
alternative to other diagnostics. If higher sensitivities are required, fluorophores which can be 
cleaved by enzymes specific to the area under investigation may be used, with high levels of 
fluorescence indicating high enzyme activity [153]. Colour change assays can also be used to 
give a higher sensitivity than through observation of phase transition into hydrogels [152].  
 
1.6.4 Poly (ethylene glycol)-based hydrogels 
PEG-based block copolymers bound to other peptide fragments also have been used in 
hydrogels. Often, the peptide will form the inner section, or core, of the nanostructure, and 
PEG will form the outside, as a shell [154]. PEG has been shown to form different structures 
when combined with different peptides, as when bound to βAβAKLVFF micelles are formed 
[154], whereas fibril structures have been seen when bound to other peptides such as FFKLVFF 
[155]. One advantage of PEG-based hydrogels is that they can be engineered to melt at 
approximately body temperature [156], and when bound to a matching substrate, they can 
also be degraded by enzymes [157]. PEG itself as a molecule is suited to hydrogel applications 
due to its inertness, low cost, biocompatibility, water solubility, and low immunogenicity [158, 
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159]. Due to the expanding knowledge of characteristics of PEG and its conjugates, it is 
becoming an increasingly viable compound in the field of biotechnology.  
 
1.7 Methods of tagging in cell culture 
There are a number of different ways molecules may be tagged when used in cell culturing. 
One of the most common methods is by using a fluorescent tag in the form of a fluorophore 
attached covalently to a functional group on the molecule. A common fluorophore used is 
fluorescein, along with some of its derivatives such as fluorescein isothiocyanate (FITC), which 
are engineered for different purposes [160]. Another method of tagging used in cell culturing 
is isotopic labelling [161]. This involves the use of an isotope which has the same 
characteristics as the normal atom and which will not interfere with normal processes. It is 
tracked as it undergoes reactions, or for its presence in certain parts of a cell, through the 
difference in mass, vibrations or radioactive decay when compared with the normally present 
atom. Deuterium oxide, or heavy water, is an example of an isotopic label where the hydrogen 
atoms are replaced with an isotope, deuterium, giving D2O. 
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1.8 Aims 
The overarching aim of the research discussed in this thesis is to investigate further into the 
self-assembly of peptide amphiphiles. This will include a range of different PAs, from short 
peptide sequences, to large, polyethylene oxide-containing molecules, to lipopeptide drugs. 
Specifically, the aims are: 
 To investigate the self-assembly of the Toll-like receptor agonists PamCSK4, Pam2CSK4, 
and Pam3CSK4, and to compare the effects of the number of palmitoyl chains. 
 To compare the self-assembly of the TLR-agonist MALP-2 with its constituent peptide 
to determine the effects of the attached lipid chains.  
 To determine whether the fluorophore FITC, when bound to a dileucine peptide motif, 
is able to be uptaken into cells, and to determine the self-assembled structure of the 
molecule above its cac.  
 To investigate the morphology of the self-assembled structure of the polyene 
antifungal drug amphotericin B. 
 To further research into the cyclic lipopeptide daptomycin, showing the morphology 
of daptomycin self-assembled structures, and investigating the proposed link between 
CaCl2 presence and micellization.  
 To investigate the self-assembly of three custom-synthesised telechelic tyrosine 
conjugates (with PEG or poly (alanine) midblocks), to determine the effect of the short 
peptide end caps and size of the central polymer block. 
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Chapter 2 – The effect of lipid chain number on the self-assembly of Toll-
like receptor agonist lipopeptides 
 
2.1 Introduction 
The innate immune system is a defence system and the first line against invading pathogens. 
In response to these pathogens, a range of pro-inflammatory mediators are released, 
simultaneously mobilising the adaptive immune system [1]. Toll-like receptors are a type of 
transmembrane receptor heavily involved in the innate immune response, found in a number 
of different organisms [2, 3]. They are expressed on the membranes of a number of different 
leukocytes, such as dendritic cells, monocytes and macrophages [4]. They detect lipoproteins 
found in bacteria, and trigger an immune reaction in response. There are a number of 
different TLRs which each detect different lipopeptides, and are located in different parts of 
the cell. Due to their importance in the innate immune response, TLR agonists have been 
labelled as an important therapeutic target, leading to the development of synthetic TLR 
agonists [5]. TLR2, activated by a large number of different bacteria, has been found to be 
unique in that it has been shown require assistance from TLR1 and 6 in order to initiate the 
majority of its cell signalling [1], (signalling through TLR2 alone has however also been 
reported [6]). It has also been found, through experimentation with macrophages from TLR-
deficient mice, that TLR2 dimerised with TLR1 and TLR6 mediate responses to different 
lipopeptides. Studies have shown that TLR1 largely recognises triacylated lipopeptides, 
compared with TLR6 which recognises diacylated [7-9].  
As part of the research into TLR agonists, it was found that lipopeptides N-acetylated via 
glycerol-linked cysteines are good stimulators of TLRs, especially TLR2 [10]. Based on Braun’s 
lipoprotein, found abundantly in the cell membrane of many gram-negative bacteria, a 
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synthetic analog was produced. This was tripalmitoyl-S-glyceryl-cysteine, or Pam3Cys, used for 
the purpose of boosting immunogenicity from influenza when bound to an MHC (major 
histocompatibility complex) epitope [11].  Using this as a starting point, a group of compounds 
were developed with differing numbers of palmitoyl lipid chains, 1, 2 and 3, attached to a CSK4 
peptide sequence, shortened to PamCSK4, Pam2CSK4, and Pam3CSK4. Studies specifically 
investigating this group of compounds have shown binding of Pam3CSK4 to the TLR1/2 
heterodimer induces the dimer into an “m” shape (shown in figure 1) due to the presence of 
an amide-bound lipid chain [12]. This extra lipid chain isn’t present on Pam2CSK4 and other 
diacylated peptides, and they therefore have a lower affinity for TLR1/2 due to an inability to 
induce a stable heterodimer. Another study revealed the reduced affinity the TLR2/6 complex 
has for triacylated peptides due to lack of binding site for the third lipid chain [13]. The lipid 
channel in TLR6 was shown through crystal structure experimentation to be blocked by two 
phenylalanines. In the case of diacylated peptides on the other hand, the heterodimerization 
of TLR2/6 gives an increased hydrophobic area in between the TLRs, which compensates for 
the lack of extra amide-bound lipid chain binding seen in the triacylated peptide-TLR1/2 
complex. 
 
 
 
 
 
 
 
Figure 1 A model of ligand-induced heterodimerization of TLR1 and TLR2. Produced by Jin et 
al. [12]. 
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Pam3CSK4, when bound to peptides, has previously been shown to induce CD8+ T-cells 
(cytotoxic T-cells which make up part of the immune system) at a greater rate than an 
adjuvant containing the Pam3CSK4 and peptide unbound to each other [14]. The effect of 
isomers on the compound’s ability to generate an immune reaction was also investigated, 
using two different isomers around C-2 on the glycerol moiety, termed Pam-R and Pam-S. It 
was found that the R-Pam epimer induced greater interleukin-12 (IL-12) secretion than the S-
Pam epimer, implying a higher degree of dendritic cell activation [15]. Despite the research 
into the binding conformations and immune response effects of the compounds, to our 
knowledge the self-assembly had not yet been investigated. The purpose of this chapter 
therefore is to shed light on the nature of their aggregation to suggest whether this may have 
an effect on their differing bioactivity.  
 
 
 
 
 
 
 
 
 
 Figure 2 The molecular structures of each of the lipopeptides: a) PamCSK4, b) Pam2CSK4, c) 
Pam3CSK4. 
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2.2 Materials & Methods 
Pam2CSK4 and Pam3CSK4 were supplied as lyophilized powders by Invivogen, both as an HCl 
salt.  Other Pam3CSK4, and PamCSK4 samples were supplied as a TFA salt, and were purchased 
from EMC Microcollections (Tübingen, Germany). These powders were dissolved in provided 
limulus amebocyte lysate (LAL) buffer solution to 0.5 wt%. LAL buffer solution is used in 
conjunction with these lipopeptides in standard bacterial endotoxin assays. The buffer 
contains different ionic species owing to the presence of extracts from horseshoe crab blood 
cells. 
 
2.2.1 Fluorescence Assays 
Fluorescence spectra were recorded with a Varian Cary Eclipse Fluorescence Spectrometer 
with samples in 4 mm inner width quartz cuvettes. The assays were performed using 1.3x10-3 – 
0.13 wt% of the lipopeptides in 2.3x10-5 wt% pyrene solution. The samples were excited at 
λex=339 nm, and the fluorescence emission was measured for λ=(360-500 nm). 
 
2.2.2 Circular Dichroism (CD)  
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK). 
Each sample (0.5 wt% lipopeptide) was placed in a cover slip cuvette (0.1 mm thick). Spectra 
are presented with absorbance A < 2 at any measured point with a 0.5 nm step, 1 nm 
bandwidth, and 1 second collection time per step in the range 20 °C – 60 °C with 10 °C steps 
on heating and 5 min equilibration at each temperature. Samples were then cooled to 20 °C 
and after a further 5 min equilibration, spectra were measured. The CD signal from the LAL 
water was subtracted from the CD data of the Pam solutions. 
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2.2.3 Small-Angle X-ray Scattering (SAXS) 
Experiments were performed on beamline BM29 at the ESRF (Grenoble, France). A few 
microliters of samples were injected via an automated sample exchanger at a slow and very 
reproducible flux into a quartz capillary (1.8 mm internal diameter), which was then placed in 
front of the X-ray beam. The quartz capillary was enclosed in a vacuum chamber in order to 
avoid parasitic scattering. After the sample was injected in the capillary and reached the X-ray 
beam, the flow was stopped during the SAXS data acquisition. The sample was thermostated 
throughout its entire travel from the injector to the quartz capillary. SAXS experiments were 
performed at 20 °C. The q = 4πsinθ/λ range is approximately 0.04-5 nm-1, with λ = 1.03 Å (12 
keV) and a 2.87 m sample-detector distance. The images were captured using a PILATUS 1M 
detector. Data processing (background subtraction, radial averaging) was performed using 
dedicated beamline software ISPYB. 
 
2.2.4 Cryo-Transmission electron microscopy (cryo-TEM) 
Experiments were carried out at the laboratories of our collaborators at Aalto University in 
Finland using a field emission cryo-electron microscopy (JEOL JEM-3200FSC) operating at 200 
kV. Images were taken using bright-field mode and zero loss energy filtering (omega type) with 
a slit width 20 eV. Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The 
specimen temperature was maintained at -187 °C during the imaging. Vitrified specimens 
were prepared using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon 
copper grids with 3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma 
cleaner just prior to use and then transferred into the environmental chamber of FEI Vitrobot 
at room temperature and 100% humidity. Thereafter, 3 μl of sample solution at 2 wt% 
concentration was applied on the grid, blotted once for 1 second and then vitrified in a 1/1 
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mixture of liquid ethane and propane at -180 °C. Grids with vitrified sample solutions were 
maintained in a liquid nitrogen atmosphere and then cryo-transferred into the microscope.  
 
2.3 Results & Discussion 
The first experiment undertaken was to determine the cac of each of the three lipopeptides 
using the pyrene fluorescence technique, also used for a number of similar lipopeptide 
compounds [16, 17]. Seen in figure 3, this clearly showed that the number of lipid chains had 
an effect on the aggregation point. PamCSK4 had a cac of 0.12 (±0.02) wt%, Pam2CSK4 had a 
cac of 0.035 (±0.003) wt%, and Pam3CSK4 had a cac of 0.003 (±0.001) wt%.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Critical aggregation concentrations of all three lipopeptides, indicated at the 
intersections of the lines. Concentration dependence of pyrene fluorescence at 373 nm. 
 46 
 
The secondary structure of the lipopeptides was then examined using CD (figure 4), which 
again showed differences between the compounds. PamCSK4 and Pam2CSK4 showed spectra 
which have previously been attributed to disordered conformations, with a minimum peak 
below 200 nm [18, 19]. Pam2CSK4 showed lower intensity, however, when compared with 
PamCSK4. These two are in contrast to the spectra from Pam3CSK4, which is attributed to β-
sheet secondary structure formation [18, 19]. This is due to the minimum peak seen at around 
217 nm, followed by a maximum at around 200 nm.  
 
 
 
 
 
 
 
 
 
 
 
Representative cryo-TEM images were obtained of all 3 lipopeptides, shown in figure 5. Here 
Pam3CSK4 was found to differ from the other 2 again as it was shown to form a population of 
worm-like micelles in amongst spherical micelles. PamCSK4 and Pam2CSK4 in contrast showed 
only spherical micelle formation. These results were used as a basis to complement our SAXS 
Figure 4 CD data of all three lipopeptides at 0.5 wt% taken at room temperature. 
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results (figure 6). Spherical shell form factors were used for PamCSK4 and Pam2CSK4, whereas 
Pam3CSK4 was fitted to a bilayer structure. The diameter of the spherical micelles observed in 
cryo-TEM images was consistent with those which fit the SAXS data. For the Pam3CSK4 
compound, the bilayer thickness of 5.3 nm found through SAXS fitting implies interlocking of 
lipid chains. This is due to the known length of hexadecyl lipid chain being in the region of 1.6 
nm, combined with the β-sheet forming hexapeptide headgroup of 6 lots of 0.33 nm, adding 
up to a total of 3.6 nm. This interdigitation of lipid chains has also previously been seen for 
other lipopeptides [16, 17]. The specific properties and dimensions of the structures these 
were fitted to are listed in table 1.  
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Figure 5 Representative cryo-TEM images of a) PamCSK4, b) Pam2CSK4, and c) Pam3CSK4. 
Figure courtesy of I.W. Hamley. 
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Figure 6 SAXS data with form factor models described in text for a) PamCSK4, b) Pam2CSK4, 
c) Pam3CSK4. The open symbols are the experimental data, the solid red lines are the model 
form factor fits described in the text, with parameters shown in figure 6. Figure courtesy of 
I.W. Hamley. 
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Spherical Micelle Form Factor 
Sample R(outer)a/nm R(inner)b/nm μc νd Gaussian 
polydispersity 
parameters 
[R(outer)]c 
Backgroundf 
PamCSK4 2.23 1.63 -0.42 0.69 N=1, σ=0.625 10 
Pam2CSK4 3.30 2.42 -0.67 0.033 N=1, σ=0.54 0.08 
Gaussian Bilayer Form Factor 
Sample t/g nm σ(core), 
σ(out)h /nm 
ν(core)i ν(out)i Gaussian 
polydispersity 
parameters 
(t)k 
Backgroundl 
Pam3CSK4 5.33 3.89, 0.82 -0.004 0.02 N=0.17, 
σ=0.71 
5.19 
 
 
SAXS form factor model fitting parameter explanations: 
a Radius of outer core of micelle 
b Radius of inner core micelle 
c Ratio of core/shell scattering contrasts 
d Shell/solvent scattering contrast (arbitrary units) 
e Gaussian peak height N and half-width σ 
f Constant background term 
 
g Bilayer thickness 
h Width for core (lipid chain) electron density, σcore, and outer (peptide) electron density, σout, 
Gaussian functions  
i Scattering contrast of lipid core of bilayer (with respect to solvent) (arbitrary units) 
j Scattering contrast of peptide units at bilayer surface (with respect to solvent) (arbitrary 
units) 
k Gaussian peak height N and half-width σ 
l As well as the constant background, the radius of the bilayer objects was fixed at 500 nm. 
Since this is much larger than t, it does not influence the shape of the scattering profile. 
 
Table 1 Parameters for SAXS fitting form factor models using SASfit software, with corresponding 
equations available online in the SASfit manual.  
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Due to the purchasing of the lipopeptides from different sources, they were present as either 
hydrochloride or TFA salts. It was therefore necessary to determine whether these states had 
any effect on the self-assembly observed. Pam3CSK4, with both salts, was investigated through 
cryo-TEM and SAXS. This lipopeptide showed the formation of the previously mentioned 
worm-like micelles when in both states, as shown in figure 7. The same was seen in SAXS 
fitting (figure 8), where the same form factor model was used for both salt types, with very 
similar parameters.  
 
 
 
 
 
 
 
 
 
Figure 7 Representative cryo-TEM images of Pam3CSK4 salts; a) TFA, b) HCl. 
a b 
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Based on the aforementioned results into self-assembly of the 3 lipopeptides, schematics are 
presented in figure 9. For PamCSK4 and Pam2CSK4, cryo-TEM and SAXS data clearly showed the 
presence of small spherical micelles, with the small radius consistent with disordered 
conformation shown through CD data. The radii of the self-assembled structures (2.2 nm for 
PamCSK4 and 3.3 nm for Pam2CSK4) are explained by the extra lipid chain in the latter leading 
to a greater physical space being used. This sequestering of the lipid chains on the inside thus 
means that the charged KKKK sequence is present on the outside, with the CS linker in 
between separating from the hydrophobic centre. The Pam3CSK4 model is based on the 
presence of worm-like micelles and the successful fitting of the SAXS data to a bilayer 
structure. These structures are rare compared with the longer twisted nanotapes usually seen 
with other lipopeptides [20]. They have however been seen by another group which used a 
peptide amphiphile containing 13 alanine residues (chosen for their tendency towards α-helix 
formation) with 3 lysine residues interspersed to increase water solubility, attached to a 
singular 16 carbon chain [21]. The schematic of Pam3CSK4 was chosen based on the bilayer 
Figure 8 SAXS data for Pam3CSK4 salt, TFA at the top, HCl at the bottom. Figure courtesy of 
I.W. Hamley. 
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SAXS and β-sheet CD data, showing a packed bilayer arrangement. It is assumed that the 
reason Pam3CSK4 did not form spherical micelles like the other 2 lipopeptides is the extra lipid 
chain constraining the packing, thus leading to the bilayer structure. As mentioned in the SAXS 
data discussion, a narrow width distribution was observed, incorporated into the proposed 
model, differing from the large distribution usually seen with nanotapes formed by 
lipopeptides. 
 
 
 
 
 
 
 
 
 
 
The effect of temperature on the lipopeptides using temperature-dependent CD was 
investigated (figure 10). Previous studies into C16 containing lipopeptides showed a change in 
structure at around 40 °C, also leading to a phase state change from gel to sol. We took 
spectra from each of the three lipopeptides at 10 °C increments from 20 – 60 °C, and then 
dropped the temperature back down to 20 °C for another measurement to determine 
whether any changes were reversible. The range 20 – 60 °C was chosen due to previous 
Figure 9 Proposed schematics of self-assembled structures of a) PamCSK4, b) Pam2CSK4, c) 
Pam3CSK4. 
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research into palmitoyl-containing lipopeptides showing it to be the chain melting 
temperature range [22]. No significant changes were found upon heating and cooling PamCSK4 
and Pam2CSK4, but were for Pam3CSK4. The latter shows a change occurring between 30 and 
40 °C, starting with β-sheet spectra and transitioning into a disordered structure at the higher 
temperatures. Upon cooling, this change was shown to be partially reversible, showing a 
return to β-sheet conformation, albeit at much lower intensity. Further investigation into 
whether the lipid chain melting may drive a change in the morphology of the self-assembled 
structures is a future area to target.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Temperature dependant CD spectra for a) PamCSK4, b) Pam2CSK4, c) Pam3CSK4. 
a b 
c 
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X-ray diffraction was attempted on the three lipopeptides through a previously used method 
of preparing higher concentration solutions, suspending a drop of the solution between two 
wax beads, and then allowing the solution to dry, ultimately forming a stalk to be analysed [23, 
24]. However, despite following this protocol we were unable to develop stalks. Due to time 
constraints and technical issues, we were also unable to analyse the compounds through FTIR 
to confirm the secondary structures we had also seen through CD.  
The purpose of this chapter was to investigate the effect that the number of lipid chains 
attached to a peptide can have on self-assembly. In this case we found that there is a 
difference when one and two chains are attached when compared with three. This may relate 
to the bioactivity of these compounds as, as previously mentioned, there is a difference in 
activation of different TLRs between the lipopeptides used in this study. To our knowledge, 
this link has not previously been made. This should therefore spark further research in the 
area of determining whether the self-assembled nanostructures have an effect on TLRs, and if 
so, by what mechanism. In the case of these particular lipopeptides, the presence of the 
cysteine linker residue as part of the peptide sequence may also be of interest, potentially to 
be used in the creation of cross-linked structures.  
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Chapter 3 - Self-assembly of Macrophage-Activating Lipopeptide (MALP-
2)  
 
3.1 Introduction 
As previously mentioned in chapter 2, Toll-like receptors (TLRs) are a type of membrane 
receptor that play an important role in the conditioning of responses to bacterial lipopeptides, 
and creating a consequential immune response. Like the PamnCSK4 samples investigated there, 
macrophage activating lipopeptide 2 (MALP-2) is another agonist of TLRs. Its molecular 
construction, shown in figure 1, consists of a GNNDESNISFKEK peptide sequence, bonded to a 
(2R)-3-((2-amino-3-oxobutyl)thio)propane-1,2-diyl dipalmitate lipid chain [1]. The “2” in the 
name MALP-2 relates to the 2 kDa weight of the lipopeptide. Lipidation of peptide chains leads 
to the compound having increased amphiphilicity, and subsequently self-assembly [2]. The 
self-assembly of the TLR agonist class and how it relates to bioactivity has not widely been 
investigated thus far. Lipopolysaccharide (LPS) and its lipid component, Lipid A, is one which 
has had some attention.  One study found that when Lipid A aggregates, it has a greater 
bioactivity than in the monomeric state [3]. With LPS, there are varying results, with one group 
reporting increased activity when in aggregated state compared with monomeric [4], but with 
another finding monomeric to have higher activity [5].   
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MALP-2, derived from Mycoplasma fermentans but now available synthetically, has been 
shown to exhibit stimulatory effects on macrophages and monocytes [6]. Using CD36, cluster 
of differentiation 36, (a cell surface receptor) as a co-receptor, it binds to the TLR2/6 
heterodimer [7]. As mentioned in the previous chapter, this is due to MALP-2 being a 
diacylated peptide [8]. Through in vivo studies, its binding to TLR2/6 has then been shown to 
cause a cascade, increasing pro-inflammatory cytokines and chemokines, along with an 
increase in infiltration by neutrophils and lymphocytes [9, 10]. It has been found that there are 
two different stereoisomers of MALP-2, with the R isomer found to be 100 times more potent 
than the S isomer [11].  
MALP-2 has been shown to have a variety of different applications. One study revealed an 
increase in leukocyte numbers and consequent suppression of early lung metastasis in mice 
[12]. Using a mouse model again, it was shown that MALP-2 was able to be used to improve 
the wound healing process through stimulation of mediators involved in early inflammation 
[13]. Another group found that in reconstructive surgery, MALP-2 could be applied to a porous 
polyethylene biomaterial used as a scaffolding to ease incorporation into the wound [14]. 
Rharbaoui et al. found that it stimulated a strong immune response in animals, highlighting 
the potential for it to be used as a vaccine adjuvant [15]. When MALP-2 was administered to 
Figure 1 The molecular structure of MALP-2. 
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mice 24 hours before infection with Streptococcus pneumoniae, many of the clinical signs of 
infection were reduced and survival rates increased when compared with mice untreated with 
the compound [9]. Reppe et al. also found local pulmonary administration of MALP-2 in mice 
infected with influenza virus significantly reduced the level of bacteria in the lungs, a common 
complication of infection by the virus [16].  
As with the PamnCSK4 samples, to our knowledge the self-assembly of MALP-2 has not yet 
been characterised. In this chapter, the self-assembly of MALP-2 will be examined, and 
compared with that of the constituent peptide sequence GNNDESNISFKEK. The purpose will be 
to evaluate and compare the effects the peptide and lipid chain components have on the 
nature of the structures formed.  
 
3.2 Materials and methods 
MALP-2 was custom synthesised by Peptide Synthetics (UK). The average molecular mass was 
2137.2 g mol-1 (expected 2135.2 g mol-1) with a purity >95%, as determined by analytical HPLC. 
The synthesis of this material is described elsewhere [1], although Peptide Synthetics have 
followed prior literature reports [17] to synthesise the lipid chain to which the peptide has 
been added by conventional stepwise solid phase peptide synthesis techniques. The starting 
material is an epoxide, (S)-(−)glycidol (Sigma-Aldrich). Samples were dissolved in water, and all 
data are presented for samples at 0.5 wt% MALP-2 in water unless stated. The peptide 
GNNDESNISFKEK was custom synthesised by Peptide Synthetics. The average molecular mass 
was 1481.52 g mol-1 (expected 1481.54 g mol-1) with purity >95% as determined from 
analytical HPLC. 
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3.2.1 Fluorescence Spectroscopy 
ANS (8-anilo-1-naphthalenesulfonic acid) and Thioflavin T (ThT) fluorescence were used in 
order to determine the cac. Spectra were recorded with a Varian Cary Eclipse fluorescence 
spectrophotometer with samples in 4 mm inner width quartz cuvettes. Pyrene assays were 
conducted using 1.3x10-3 – 0.13 wt% of MALP-2 in 2.3x10-5 wt% pyrene solution. The sample 
was excited at λex=339 nm, and the fluorescence emission was measured for λ= 360-500 nm. 
ANS, a fluorophore, is a probe sensitive to hydrophobic environments and so is suitable for 
these cac experiments [18]. Samples were excited at λex=356 nm, and the fluorescence 
emission was measured for λ= 400-670 nm, using a 74 μM ANS solution to solubilise the 
peptide. ThT is used in cac assays in order to detect formation of amyloid-like structures such 
as β-sheets, and thus is used in cac assays for amyloid fibril-forming peptides [19]. Samples 
were excited at λex=440 nm, and the fluorescence emission was measured for λ= 460-600 nm, 
and the peptide dissolved in a 5.0 x 10-3 wt% ThT solution. 
 
3.2.2 Fourier Transform Infra-Red (FTIR) Spectroscopy 
Variable temperature FTIR experiments for MALP-2 and GNNDESNISFKEK were performed 
using a PerkinElmer Spectrum II FTIR spectrometer. Solutions in D2O were sandwiched 
between two CaF2 plate windows, with a 0.0533 mm thick Teflon spacer. The plate sandwich 
was heated and cooled using a Specac 4000 series high stability heating controller, and a 
Specac electrical heating jacket. Experiments were performed by increasing the temperature 
from 25 to 60 °C with a 5 °C step at a rate ∼1 °C/min. The temperature was then reduced to 25 
°C at a rate ∼2 °C/3 min. A D2O background spectrum was subtracted from the spectrum of 
each sample. For temperature-dependent FTIR, the D2O spectra was measured as a function of 
the temperature and subtracted from the FTIR of the sample at the corresponding 
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temperature. After D2O subtraction, a constant baseline of 0.013 and -0.003 was subtracted 
from the spectra for MALP-2 and GNNDESNISFKEK respectively.  
 
3.2.3 Circular Dichroism (CD) 
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK). 
Each sample was placed in a cover slip cuvette (0.1 mm thick). Spectra are presented with 
absorbance A < 2 at any measured point with a 0.5 nm step, 1 nm bandwidth, and 1 second 
collection time per step. For MALP-2, samples were measured in the range 25 °C – 70 °C with 
10 °C steps on heating and 2 min equilibration at each temperature. 0.5 wt% MALP-2 was 
used. For GNNDESNISFKEK, solutions were measured using parallel plaques (0.01 mm gap) for 
concentrations 0.5-2 wt% and a quartz cuvette (1 mm thick) for 0.008 wt%. The CD spectra for 
0.008-1 wt% were smoothed using the Chirascan software, confirming that the residual trace 
shows only noise randomly distributed about zero. 
 
3.2.4 Small-Angle X-ray Scattering (SAXS) 
SAXS experiments were performed on beamline B21 at Diamond (Harwell, UK) using a BioSAXS 
robot. Solutions were loaded into the 96-well plate of an EMBL BioSAXS robot and then 
injected via an automated sample exchanger into a quartz capillary (1.8 mm internal diameter) 
in the X-ray beam. The quartz capillary was enclosed in a vacuum chamber, in order to avoid 
parasitic scattering. After the sample was injected into the capillary and had reached the X-ray 
beam, the flow was stopped during the SAXS data acquisition. B21 operated with a fixed 
camera length (3.9 m) and fixed energy (12.4 keV). The images were captured using a Pilatus 2 
M detector. Data processing, including background subtraction and radial averaging, was 
performed using the dedicated software Scatter.  
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3.2.5 X-ray Diffraction (XRD) 
XRD was performed on a peptide stalk prepared by drawing a fiber of a 1 or 10 wt% peptide 
solution between the ends of wax-coated capillaries. After separation of the capillaries and 
drying, a stalk was left on the end of one capillary. MALP-2 stalks were mounted vertically 
onto the goniometer of an Oxford Instruments Gemini X-ray diffractometer, equipped with a 
Sapphire 3 CCD detector. The sample-to-detector distance was 45 mm. GNNDESNISFKEK stalks 
were mounted vertically onto the four axis goniometer of a RAXIS IV++ X-ray diffractometer 
(Rigaku) equipped with a rotating anode generator, while the XRD data was collected using a 
Saturn 992 CCD camera. The sample-to-detector distance was 50 mm. CLEARER software [20] 
was used to reduce the 2D data to a one-dimensional intensity profile. 
 
3.2.6 Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Experiments were carried out at the laboratories of our collaborators at Aalto University in 
Finland using a field emission cryo-electron microscopy (JEOL JEM-3200FSC) operating at 300 
kV. Images were taken using bright-field mode and zero loss energy filtering (omega type) with 
a slit width 20 eV. Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The 
specimen temperature was maintained at -187 °C during the imaging. Vitrified specimens 
were prepared using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon 
copper grids with 3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma 
cleaner just prior to use and then transferred into the environmental chamber of FEI Vitrobot 
at room temperature and 100% humidity. Thereafter, 3 μl of sample solution at 0.5 wt% 
concentration was applied on the grid, blotted once for 1 second, and then vitrified in a 1/1 
mixture of liquid ethane and propane at -180 °C. Grids with vitrified sample solutions were 
maintained in a liquid nitrogen atmosphere and then cryo-transferred into the microscope.  
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3.3 Results and discussion 
Firstly, the cac of MALP-2 was determined using pyrene fluorescence assay, described in more 
detail in chapter 2. Figure 2 shows the experimentally determined cac, giving a value of         
5.7 x 10-2 (± 0.02) wt%.  
 
 
 
 
 
 
 
 
 
 
 
 
The secondary structure of MALP-2 was then probed through a combination of CD and FTIR 
spectroscopy, and using temperature dependence as in chapter 2 to determine whether there 
was any lipid chain melting. CD was first to be measured over a range of temperatures from 20 
°C to 60 °C and then after cooling back down to 20 °C to determine whether any change was 
reversible. The results, shown in figure 3, clearly show a β-sheet spectrum based on the 
Figure 2 Critical aggregation concentrations of MALP-2 through pyrene fluorescence, indicated at 
the intersections of the lines. Concentration dependence of pyrene fluorescence at 373 nm. 
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minimum at 220 nm and a maximum at around 200 nm [21, 22]. There is no significant change 
in structure upon heating, aside from a slight reduction in molar ellipticity around the 200 nm 
maxima peak. 
 
 
 
 
 
 
 
 
 
 
In the preparation of the MALP-2 samples, it was found that heating the sample up before 
experimentation gave more consistent results, potentially related to the poor solubility of 
MALP-2 without heating. For the FTIR measurements seen in figure 4 therefore, the solution 
was heated up to 60 °C initially, before cooling at 10 °C steps. This was in contrast to the usual 
protocol which raises the temperature at 10 °C intervals, at which measurements are then 
taken. In figure 4a, there is a gradual decrease in intensity of the broad 1454 cm-1 peak upon 
cooling. Due to issues seen around the time of experimentation, this can partly be attributed 
to evaporation from the FTIR cell.  This peak can be attributed to methyl and methylene 
groups [23]. The peak at 1620 cm-1, which doesn’t change significantly in intensity above the 
Figure 3 Temperature-dependent CD of 0.5 wt% MALP-2. 
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baseline in accordance with change in temperature, can be linked with the presence of β-
sheets [24], and which agrees with β-sheet formation seen by CD. The small peak at 1672 cm-1 
has also been seen before and is due to presence of TFA counterions [25], present in the 
MALP-2 sample and on a number of other manufactured lipopeptides, such as the PamnCSK4 
group [26].  
Observing the spectra from 2800 – 3100 cm-1, which shows the area of CH2 stretching in lipid 
chains [27], of which MALP-2 has many CH2 groups, two small peaks can be seen at 2850 cm-1 
and 2920 cm-1 (figure 4b). There is a lowering in intensity of peaks throughout the 
wavenumber range with decreasing temperature; however they are not restricted to the two 
peaks seen. It can therefore be suggested that the previously mentioned problem of 
evaporation in FTIR cell is responsible.  
 
 
 
 
 
 
 
 
Fibre XRD of MALP-2 was performed next to complement the spectroscopic data attained 
through CD and FTIR. The XRD pattern was found to be isotropic, and thus was reduced to a 
1D intensity profile, shown in figure 5. The peaks seen in figure 5b were shown to be 
Figure 4 FTIR spectra of 0.5 wt% MALP-2 solution in D2O. Temperature ramp from 60 – 20 °C. 
Wavenumber range a) 1300 – 1800 cm-1, and b) 2800 – 3100 cm-1.  
a b 
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associated with d-spacings of 12 Å, 4.72 Å, and 4.23 Å. The 12 Å peak can be attributed to the 
spacing between the β-sheet structures, and the 4.72 Å peak to spacing between the β-
strands. These are expected values for “cross-β” fibre diffraction patterns [28, 29].  
 
 
 
 
 
 
 
 
 
Cryo-TEM images of MALP-2 in solution were obtained by collaborators at the University of 
Aalto, Finland, shown in figure 6. There appears to be a mixture of individual tape-like fibers, 
alongside large masses of the fibers crossing and interlinked with others. The length of each 
fiber seems to have a large variation, from less than 100 nm to many hundreds of nanometres, 
but the width is fairly uniform.  
 
 
 
 
Figure 5 XRD data from 1 wt% stalk MALP-2 solution. a) 2D image, b) XRD 
intensity profile. 
a b 
 69 
 
 
 
 
 
 
 
 
 
At this point in the research, it was found that there were problems with preparation of the 
MALP-2 sample in achieving full dissolution. After a new compound from a different source 
was used, a colleague, Valeria Castelletto, repeated all experiments that had been undertaken 
so far.  These repeated results can be seen in the full paper [30]. The cac measurements were 
repeated, with results shown in figure 7. The less toxic ANS [18, 31, 32], along with ThT [19, 
32] were used, and it was found that the cac was less than ten times as high as the one 
determined using pyrene, with the wt% values from both methods being nearly the same.  
 
 
 
 
 
 
Figure 6 Representative cryo-TEM images of 0.5 wt% MALP-2. 
a b 
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CD results were the same, with both versions showing β-sheet formation, and FTIR was also 
fairly similar, albeit with more pronounced peaks in V. Castelletto’s experiments. XRD showed 
additional lower q-range peaks which corresponded to the distance between peptides or 
chains within the structures. Cryo-TEM images also showed the long tape-like fibers, but also 
appeared to show much more organised raft-like structures formed from bound adjacent 
fibers (figure 9a).  
Structures observed through cryo-TEM were then used as an input to constrain the form 
factor fitting of the raw SAXS data and to give specific structural parameters. SAXS data 
obtained over the temperature range also used in CD are shown in figure 8. The SAXS data 
were fitted to a bilayer structure, which show a slight increase in thickness from 30 Å to 35 Å 
across the temperature range. Parameters are shown in table 1. 
 
Figure 7 Comparison of fluorescence assays using pyrene, ANS and ThT. 
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Figure 8 SAXS profiles of 0.5 wt% MALP-2 at a range of temperatures, from 20 – 60 °C, and 
then cooled back down to 20 °C. Black symbols represent data points, red line represents 
the fit. Figure courtesy of V. Castelletto. 
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Parameter 20 °C 30 °C 40 °C 50 °C 60 °C 20 °C cooled  
Na [arb. Units] 1.08 1 1.27 1.16 1.01 1 
Δb [Å] 18.4 17.6 18.18 17.95 18.76 17.88 
tc [Å] 30.08 30 30.02 34.7 35.93 31.2 
σНd [Å] 4.74 5.08 4.67 5.1 5.76 5.3 
ρНe [rel. units] 1.69x10-7 1.72x10-7 1.47x10-7 1.02x10-7 1.31x10-7 1.59x10-7 
σcf [Å] 4.13 5.23 4.92 6.8 6.786 5.47 
ρcg [rel. units] -3.69x10-8 -1.04x10-8 -3.67x10-8 -5.7x10-8 -3.06x10-8 -3.9x10-8 
Coh [arb. 
Units] 
2x10-5 4x10-5 9x10-5 1x10-5 1.3x10-4 3x10-6 
 
SAXS form factor model fitting parameter explanations: 
a Scale factor 
b Gaussian half-width at half-maximum for polydispersity in layer thickness c 
d Gaussian half-width for outer layer surface (“headgroup”) 
e Relative electron density for headgroup 
f Gaussian half-width for inner layer 
g Relative electron density for inner layer 
h Constant background  
 
Experiments on the peptide GNNDESNISFKEK were all performed by V. Castelletto. It was 
found that, in contrast to MALP-2, it dissolved very readily in water. It also had a measured 
isoelectric point at 4.44 in water, similar to the measured MALP-2 at 4.68 [33]. The cac was 
determined using ANS and ThT fluorescence assays, and was found to be 0.49 wt%, and 0.54 
wt% respectively. As with MALP-2, these two values are very similar, and so it can be deduced 
that the fibril formation and that of the hydrophobic pockets occur concurrently.  
Table 1 Parameters for SAXS fitting form factor models using SASfit software, with 
corresponding equations available online in the SASfit manual.  
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A range of concentrations, from 0.5 to 10 wt% were used to determine the secondary 
structure through CD and FTIR. CD showed a transition from an unordered structure below the 
cac, to a β-sheet with β-turns, whilst FTIR also showed shifted peaks correlating to β-sheets. 
XRD, combined with SAXS data, were used to produce a model with an arranged β-sheet core, 
with a surrounding outer layer of hydrophilic residues. Cryo-TEM images showed fairly 
uniform twisted tapes with lengths up to micrometres, with antiparallel bilayer structure; 
hydrophobic core on the inside, with hydrophilic lysine residues on the outside (figure 9b).  
 
 
 
 
 
 
 
 
 
The purpose of this research was to investigate the influence lipid chains have on the self-
assembly of peptides. In this case, the presence of two lipid chains enabled interactions 
between otherwise individual fibers, and were able to form a raft-like structure composed of 
β-sheets above a cac. Self-assembly in compounds which have high hydrophobic lipid chain 
interaction usually lead to the formation of bilayered structures, whereas high β-sheet content 
generally leads to formation of fibrils [34]. These raft-like structures therefore pose an 
Figure 9 Representative cryo-TEM images from a) a 0.5 wt% solution of MALP-2, b) a 2 wt% 
solution of GNNDESNISFKEK. Figure courtesy of V. Castelletto [30]. 
a b 
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interesting question of how they are formed, especially due to the lack of any other findings of 
raft-like structure formation from lipopeptides in literature. They may be intermediates 
between a bilayered planar nanosheet and a fibril structure, with a fine line between 
formation of one of these.  
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Chapter 4 - Addition of dileucine motif to FITC fluorophore enables use 
in cell labelling  
 
4.1 Introduction 
The effect lipid chains attached to peptides can have on self-assembly has already been 
discussed, but as well as those, aromatic side chains also have the ability to modify self-
assembly, through hydrophobic effects as well as stacking interactions between the aromatic 
moieties. There are a number of often used substituents, including Fmoc [9-
fluorenylmethoxycarbonyl chloride] [1-3], Boc [tert-butyloxycarbonyl] [4, 5], naphthalene [6-
8], pyrene [8, 9], and also fluorene [8]. These are usually used in order to make 
hydrogel/organogel formulations. Attached conjugates may be used in biomedical 
applications, in some cases through direct influence of the amino acids present. One study 
which used a peptide sequence attached to a number of different fluorophores found that 
they each self-assembled differently to each other, and one had the effect of maintaining cell 
adhesion due to inhibition of an actin toxin [10]. The attachment of functional units, including 
Nonsteroidal anti-inflammatory drugs (NSAIDs), can also be used. Upon addition of an NSAID, 
in this case Naproxen, to D-amino acids, it was found that proteolytic resistance increased, as 
did selectivity of Naproxen for COX-2, an enzyme involved in the inflammation and pain 
response [11]. The same group also investigated the effect conjugation of a small peptide to a 
range of NSAIDs would have on self-assembly and bioactivity [12]. They found further 
evidence of molecular nanofiber formation, and also increased target selectivity for NSAIDs, as 
well as preservation of activities in those NSAIDs bound to D-amino acids. Li et al. also used 
Taxol as a conjugating moiety, and upon attachment to phosphorylated D-peptides produced 
different precursors which were able to form biostable or biocompatible hydrogels [13]. There 
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are also a number of other therapeutic agents used as conjugates bound to peptides with uses 
in biomedical applications, listed in more detail by Zhao et al. [14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, we investigated a peptide amphiphile consisting of a bulky hydrophobic 
fluorophore, fluorescein isothiocyanate (FITC), attached to a di-leucine peptide motif at the N-
terminus (shown in figure 2). It was developed as a custom synthesised peptide for the 
potential to be used in cell labelling with its added biocompatibility. FITC has previously been 
b a 
c 
Figure 1 Molecular structure of a range of aromatic substituents, described in the text, 
including a) pyrene, b) Naproxen, and c) Taxol. 
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used in cellular fluorescence labelling when bound to a peptide chain [15]. Xentry, a short 
peptide sequence of LCLRPVG, is a cell penetrating peptide (CPP) derived from the hepatitis B 
virus, and was visually able to be seen within cells due to the fluorescence from FITC. A novel 
peptide chain, KRKRWHW, was developed as a CPP to have a lower cytotoxicity and to deliver 
non-permeable trehalose into cells [16]. The peptide chain was attached to FITC to determine 
the location in which it accumulated. FITC was also used bound to another peptide chain, 
YG(R)9, to determine the localisation of its accumulation in cells [17].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Molecular structure of FITC-LL. 
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4.2 Materials and methods 
FITC-LL was synthesised by Dr A.M. Smith using FITC and LL initially as separate compounds. 
The mass was 634.5 g mol-1 (measured), 635.73 g mol-1 (expected). The full synthesis protocol 
can be found in the supplementary data of the published paper [18]. 
For the self-assembly studies, in order for the FITC-LL to form a solution or gel (at higher 
concentration), pH had to be controlled. Distilled water was first added to the FITC-LL powder 
to total between a third and a half of the target final total volume in order to establish a 
concentration of around 5 mg/ml. 1 M NaOH was added at a quarter of the target final total 
volume of in order for the FITC-LL to dissolve in the solution, with gentle swirling, to raise the 
pH to 9-10. A solution of 1M HCl was then titrated to lower the pH to below 7 to form the 
solution or gel, with incubation in the fridge at 2-5 C sometimes needed for gel formation. Due 
to their light-sensitive nature, the FITC-LL compound and solutions were shielded from light 
when possible.  
 
4.2.1 Fluorescence Spectroscopy 
The cac was determined through a concentration-dependent fluorescence assay. Fluorescence 
spectra were recorded with a Varian Cary Eclipse Fluorescence Spectrometer with samples in 
10 mm inner width quartz cuvettes. The fluorescence assays were performed using 0.05 – 0.4 
wt% FITC-LL solutions in distilled water. The samples were excited at ex= 495 nm, and the 
fluorescence emission was measured for = (480-650) nm.  
 
4.2.2 Circular Dichroism (CD) 
Spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK). A 
solution of FITC-LL in water (0.4 wt%) was placed in a cover slip cuvette (0.01 mm thick). 
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Spectra are presented with absorbance A < 2 at any measured point with a 0.5 nm step, 1 nm 
bandwidth, and 1 second collection time per step at 20 C. The post-acquisition smoothing 
tool in the Chirascan software was used to remove random noise elements from the averaged 
spectra. A residual plot was generated for each curve in order to verify whether or not the 
spectrum has been distorted during the smoothing process. The CD signal from water was 
subtracted from the CD data of the peptide solutions.  
 
4.2.3 Fourier Transform Infra-red (FTIR) spectroscopy 
Spectra were recorded using a Thermo Scientific Nicolet IS5 and a Nexus-FTIR spectrometer, 
both equipped with a DTGS detector. A solution of FITC-LL (0.73 wt% in water) was 
sandwiched between two CaF2 plate windows (spacer 0.012 or 0.025 mm thick). Spectra were 
scanned 128 or 168 times over the range of 900-4000 cm-1.  
 
4.2.4 Cryo-Transmission electron microscopy (cryo-TEM) 
Experiments were carried out by our collaborators at Aalto University in Finland using a field 
emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 300 kV. Images were 
taken using bright-field mode and zero loss energy filtering (omega type) with a slit with 20 eV. 
Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The specimen 
temperature was maintained at -187 °C during the imaging. Vitrified specimens were prepared 
using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids with 
3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma cleaner just prior to 
use and then transferred into an environmental chamber of FEI Vitrobot at room temperature 
and 100% humidity. Thereafter, 3 μl of sample solution at 2 wt% concentration was applied on 
the grid, blotted once for 1 second and then vitrified in a 1/1 mixture of liquid ethane and 
propane at -180 °C. Grids with vitrified sample solutions were maintained in a liquid nitrogen 
atmosphere and then cryo-transferred into the microscope.  
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4.2.5 Human fibroblast cell culturing and cell viability and uptake assays 
4.2.5.1 Cell culture 
Human corneal fibroblasts were isolated and cultured as previously described [19], by R. 
Gouveia. Upon confluence, cells were passaged by gentle wash with phosphate buffered saline 
(PBS) followed by 5 min incubation with TrypLE enzyme (Life Technologies), mechanical 
dislodgement, centrifugation at 500 ×g for 5 min, re-suspension in fresh culture medium, and 
seeding to new tissue culture flasks. Cells up to passage four were used in subsequent 
experiments. 
 
4.2.5.2 FITC-LL uptake assays 
Cells were seeded into 24-well plates at 1×105 cells/cm2 and cultured with serum-free medium 
for 48 h at 37 °C. Cultures were washed thrice with PBS and incubated with serum-free culture 
medium containing 7.5x10-3 wt% FITC-LL or non-conjugated FITC control for 24 h at 37 °C. Cells 
were then washed thrice with PBS to remove all non-internalised fluorophore, and imaged by 
bright-field and fluorescence microscopy using the LumaScope 500 inverted fluorescence 
microscope (Etaluma). To examine FITC-LL intracellular localization, cells were treated as 
described above, but with the additional step of adding the 4',6-diamidino-2-phenylindole 
(DAPI) nuclear stain (Life Technologies) just prior to imaging using the AxioVert 200 inverted 
fluorescence microscope (Zeiss). Bright-field and fluorescence signals were obtained using 
independent channels, which were then composed post-imaging using the ImageJ software 
(version 1.49). Uptake assays were performed in duplicate, in three independent experiments 
using different cell donors. 
 
 84 
 
4.2.5.3 Cell viability assays 
Cells were seeded into glass coverslips in 24-well plates at 1×105 cells/cm2 and cultured with 
serum-free medium for 48 h at 37 °C. Cultures were washed thrice with PBS and incubated 
with serum-free culture medium containing 7.5x10-3 wt% FITC-LL or non-conjugated FITC 
control for 24 h at 37 °C. Cells were then washed thrice with PBS to remove all non-
internalised fluorophore, and incubated with Live/Dead cell Double Staining kit (Calbiochem) 
according to the manufacturer’s instructions. Briefly, the green-fluorescent, membrane-
permeable Cyto-Dye and the red-fluorescent, membrane-impermeable propidium iodide were 
added to staining buffer at the 1:1:1000 ratio. Cell were incubated with these dyes for 15 min 
at 37 °C, washed thrice with PBS to remove all unbound dye, and imaged by fluorescence 
microscopy using the AxioVert 200 inverted fluorescence microscope (Zeiss). Green and red 
fluorescence signals were obtained using independent channels, and then composed post-
imaging using the ImageJ software (version 1.49). Cell viability assays were performed in 
duplicate, in two independent experiments using different cell donors. 
 
4.3 Results and discussion 
4.3.1 Self-assembly studies 
The self-assembly of FITC-LL in aqueous solution was investigated. As with the other chapters, 
this began with fluorescence measurements to determine the critical aggregation 
concentration (cac) of FITC-LL. Due to the compound having its own documented self-
fluorescence properties, we performed a concentration-dependent assay over a range of 
concentrations, but without the addition of pyrene, ANS or ThT. Using FITC’s documented 
excitation peak of 495 nm [20], the broad emission peak was found at 525 nm. It was found 
that at the higher concentrations, fluorescence diminished, leading to the belief that there is a 
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self-quenching effect when self-assembled structures are formed. The cac was determined to 
be 0.25 wt% (figure 3).   
 
 
 
 
 
 
 
 
 
 
 
Next the secondary structure of the compound was investigated through the use of CD and 
FTIR. In the latter spectrum, shown in figure 4, there is a peak in the amide I region at 1633 
cm-1. This peak can be attributed to β-sheet formation [21]. There is also a larger peak at 1578 
cm-1, the amide II region, which is attributed to stretching of C—N/ bending of N—H [22].  
 
 
 
Figure 3 Critical aggregation concentration of FITC-LL, fitted through a sigmoidal 
curve (red line), and cac obtained from the minimum of the first derivative (black 
line). 
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In contrast to the corresponding β-sheet peak seen in the FTIR data, the CD spectrum in figure 
5 does not show a curve which typically resembles that of a β-sheet structure. This is usually 
characterised by a maximum at around 200 nm combined with a negative at around 216 nm 
[21, 23]. This however may in part be due to the UV absorbance seen with FITC (in figure 6) 
[24, 25], as well as the presence of the highly extended nanostructures. The wavelength range 
studies for the compound was extended up to 550 nm in order to examine any chiral ordering 
of FITC due to its attachment to the dipeptide. Indeed, a broad peak was observed at around 
520 nm.  
 
 
 
Figure 4 FTIR spectrum of 0.73 wt% FITC-LL solution in D2O.  
1633 
1578 
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Figure 5 CD spectrum from 0.4 wt% FITC-LL solution. 
Figure 6 Spectra of FITC absorbance/emission. Blue line denotes excitation, red line 
denotes emission. Figure from reference [25]. 
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The next step was sending samples off to our collaborators at the University of Aalto in Finland 
for cryo-TEM. The images (figure 7) showed the formation of large sheets of varying size and 
width. It can also be seen that the sheets have thin edges, seen particularly in figure 6a within 
the black circle. These sheets are particularly interesting as, to our knowledge; these 
structures have not previously been seen with dipeptide motif attached to bulky aromatic 
substituents. Instead, short peptide sequences attached to aromatic conjugates typically form 
fibrils [2, 26, 27].  
 
 
 
 
 
 
 
 
 
As with the other chapters, we used the cryo-TEM images as a constraint to the form factor 
modelling of SAXS data. In figure 8, it is shown that the data was fitted accurately to a 
Gaussian bilayer model, which has also been used by other colleagues in the research group 
previously to fit other layered peptide assemblies [28-30]. Although FITC-LL did not form a 
bilayer as such, the parameters within the form factor mean that the dileucine motif is seen as 
Figure 7 Representative cryo-TEM images from a 0.73 wt% solution. 
a b 
 89 
 
the outer layer of the bilayer, and FITC as the inner layer. The specific properties and 
dimensions of the structures it was fitted to can be found in table 1. 
 
 
 
 
 
 
 
 
 
 
Gaussian bilayer form factor 
Layer 
thickness (t) 
Lipid core 
(ρc) 
Headgroup 
(ρh) 
Background 
(B) 
Gaussian 
function 
width 
(fixed) 
Bilayer 
radius 
(fixed) 
Scaling 
factor (F) 
8.9 -2.36 x 10-5 6.4 x 10-6 0.0004 5 Å 500 Å 0.001 
 
Cell assays 
 
4.3.2 Cell viability and compatibility studies 
After investigating the self-assembly and the nature of the formed structures, FITC-LL’s effect 
on cells was determined. Initially it was tested whether FITC-LL, and the fluorophore FITC on 
Table 1 Parameters for SAXS fitting form factor models using SASfit software, with 
corresponding equations available online in the SASfit manual.  
Figure 8 SAXS data (open black symbols) with model form factor fit (red line).  
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its own, was toxic to cells through a live/dead cell assay. This showed live cells in green and 
dead cells in red. As can be seen in figure 9, incubation with either FITC or FITC-LL showed no 
toxicity to cells, demonstrated by a lack of red-stained cells in both images. 
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Figure 9 Representative images showing live/dead cell assay of a) FITC-LL, and b) FITC, both 
at 7.5 x 10-3 wt% incubated with human fibroblasts. Green fluorescence indicates live cells, 
red indicates dead cells.  
b 
a 
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As the lack of toxicity was established, the next objective was to determine whether the 
compounds were able to be uptaken by cells. Figure 10 shows the comparison between the 
uptake of FITC when compared with FITC-LL. There is a clear difference between the two, with 
FITC-LL very readily being uptaken into cells, compared with FITC which has specks of green 
fluorescence. These specks may be explained through the washing of the cells, rather than any 
cellular uptake, due to the aggregated nature of the fluorescence and the presence of it 
outside of cells. FITC-LL on the other hand was shown to be uptaken by the majority of cells, 
with very little fluorescence outside of them.  
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a 
b 
Figure 10 Representative images showing uptake cell assay of a) FITC-LL, and b) FITC, both at 
7.5 x 10-3 wt% incubated with human fibroblasts. Green fluorescence is from intrinsic 
fluorescence of the fluorophore, which shows cells have uptaken the compound. 
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In order to discover more on the regions of the cell FITC-LL is uptaken into, a nuclear staining 
dye, DAPI (4′,6-diamidino-2-phenylindole), was also incubated alongside the compound, and 
higher resolution images were taken by one of our collaborators at Newcastle University. In 
figure 11, it appears that FITC-LL is present throughout most of the cell, potentially with a 
small amount also present in the nucleus, shown by the slight overlap of FITC green and DAPI 
blue fluorescence. However, it can’t be confirmed due to the two dimensional nature of the 
images. The images do show a large localisation of FITC-LL in the peri-nuclear region, shown 
through light blue staining, and inside vesicle-shaped intracellular compartments, indicated by 
the arrows in figure 11b. Further experiments were due to be undertaken to create a 3 
dimensional view of how the compound is uptaken, to further characterise the localisation of 
FITC-LL in the cell. However, the collaboration with the group involved with the cellular section 
ended before the experiments were able to be done.  
 
 
 
 
 
 
 
 
 
Figure 11 Representative images of fibroblasts incubated with 7.5 x 10-3 wt% FITC-LL and 
stained with nuclear stain DAPI. The scale bars correspond to 20 μm. Experiments performed 
by R.M. Gouveia at Newcastle University. 
a b 
20 μm 20 μm 
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The aims in this chapter were to characterise the self-assembly properties of a bulky aromatic 
fluorophore bonded to a dileucine motif. It was shown that FITC-LL is able to self-assemble 
above a cac, at which self-quenching, potentially due to the formation of the structures, 
occurs. FTIR and CD data appeared to show conflicting data, with the former showing peaks 
which could be attributed to β-sheet formation, not seen in the CD spectra. This however 
could potentially have been due to other factors such as the UV absorbance and presence of 
extended nanostructures, seen in cryo-TEM and its dimensions revealed through SAXS. 
Another aim in the chapter was to determine the cytocompatibility and uptake in cells. Here, it 
was proven that the bonding of the dileucine motif to FITC enabled it to be uptaken into cells, 
when compared with the fluorophore on its own, and that neither was cytotoxic.  
Future work concerning FITC-LL could focus on the mechanism of how such a short peptide 
sequence enables a compound to be uptaken, and whether this is specific to dileucine. As the 
peptide sequence is too short to be a transporter sequence, there must be another 
mechanism involved. There is potentially a correlation between self-assembly and FITC-LL 
uptake through a local concentration enhancement in close proximity to the cell membrane. 
The FITC-LL concentration used in the cell studies was below the cac, so localised increase of 
the compound near to the membrane would need to occur in order for the theory to be 
correct. The large lack of FITC-LL in the nucleus may be explained through the fact that Nuclear 
Export Signals (NES), short amino acid sequences found on molecules which allow for export 
from the nucleus, are leucine-rich [31, 32]. It is therefore possible that the movement of FITC-
LL is facilitated through these NES systems through the dileucine sequence.  
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Chapter 5- The self-assembly of commercially available anti-fungal drug 
Amphotericin B 
 
5.1 Introduction 
In this chapter, the self-assembly of a macrolide polyene antifungal drug, Amphotericin B 
(AmB), is considered. It is produced by a soil actinomycete called Streptomyces nodosus and 
has been used in medicine since approval by the FDA in 1959 [1]. When used therapeutically, 
it is usually combined with a detergent, often sodium deoxycholate, and then administered 
intravenously [2].  Examples of these formulations include Fungizone and AmBisome [3, 4]. 
These formulations are also required as AmB is not water soluble at neutral pH [5]. Despite its 
long use, it has retained good antifungal properties against a large spectrum of targets, 
including many Candida and Aspergillus species, and other filamentous fungi, including 
Mucorales [6]. Its structure is shown in figure 1, and consists of a hydrophobic polyene 
backbone on one side, and a hydrophilic side consisting of hydroxyl groups, and a carboxyl and 
mycosamine group.  
 
 
 
 
 
 
 Figure 1 The molecular structure of amphotericin B. 
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Its mechanism of activity involves binding selectively to ergosterol, found in fungal cell 
membranes but not in humans, where cholesterol is instead present [7], and formation of a 
pore. There is thought to be some binding to cholesterol, but at much lower affinity [8]. 
Ergosterol is a critical part of the physiology of yeasts which performs many of the same 
functions in fungi as cholesterol does in animal cells, namely to influence membrane rigidity, 
fluidity and permeability [9]. It has been shown that mutations which alter the biosynthesis of 
ergosterol, and thus would offer resistance, have led to a decrease in virulence [10]. This 
therefore contributes to amphotericin B’s evasion of fungal resistance thus far. 
The two domains previously mentioned, hydrophobic and hydrophilic, play a key role in its 
activity. The hydrophobic regions of AmB, through the polyene backbone, interact to form 
dimers, and then further interact to stack together and form a helical array [11]. These 
interactions are required as the monomeric form of AmB is not believed to be able to 
permeate the membrane on its own [12]. Pore formation in the membrane causes the rapid 
outflow of K+ and Mg2+ ions, as well as fungal glycolysis inhibition and subsequent influx of 
protons into the cell [13]. This causes acidification of the fungal cell, leading to cytoplasm 
precipitation, and finally death of the cell. 
A large proportion of the research around AmB has involved how the drug reacts in 
formulations. One such study investigated self-assembly of AmB and heavily influenced the 
research undertaken in this chapter [14]. The structures formed by AmB in a range of different 
solvents that simulate physiological environments were investigated, and it was found that 
AmB was present in two different dimer forms, parallel and anti-parallel. These can then 
further self-assemble, shown by time evolution CD spectra, to form tetramers. These 
structures were previously investigated through fluorescence spectroscopy by members of the 
same group [15]. The authors suggest that the dimer form of AmB is the one responsible for 
the toxicity seen in with the drug, which can then associate into tetramers responsible for the 
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transmembrane pore. Grudzinski et al. also used fluorescence lifetime imaging microscopy to 
investigate AmB in a singular bilayer system, finding the most favourable conditions for 
entering the lipid phase, including the structure and orientation [16].   Block copolymers have 
also been used in order to increase the water-solubility of AmB, although release from these 
vectors was shown to either be slow or they did not release at all [17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Visualisation of simulations showing the range of geometries and structures 
amphotericin B is proposed to be present in or able to form. I-IV show dimer structures, and 
tetramer structures are shown by p-a (parallel-antiparallel), a-a (antiparallel- antiparallel), 
and p-p (parallel-parallel). [32] 
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This research aims to build upon existing knowledge of the self-assembly of AmB in water. To 
our knowledge, the assembly of AmB has not been investigated at concentrations as high as 
we have used here. The samples used in these experiments however will also have the pH 
adjusted to 12 in order to keep increase the solubility, such as in other papers [14]. AmB at pH 
above 10 has also been shown to be present in the monomeric form, owing to the negative 
electric charge on the molecule [18]. DMSO is also used in the fluorescence lifetime imagine 
microscopy (FLIM) experiments in order to test the results from a previous paper [14]. A 
number of solvents known to present AmB in the forms of monomer, dimer and tetramers 
were used in this study. With the dimer form, it was found that there were two different 
photon lifetimes, caused by a parallel and antiparallel dimer. The percentage of each lifetime 
fraction also varied between solvent types, polar protic, polar aprotic and nonpolar. Water 
alkalised to pH 12 and DMSO were chosen in our research in order to compare the results of 
solvents with differing polarities. 
 
5.2 Materials and methods 
Amphotericin B (AmB) was obtained in the form of powder from Merck Millipore (Nottingham, 
U.K.). The purity of the compound was determined by analytical HPLC to be 92.5%, and the 
molecular weight was obtained by electrospray-mass spectrometry (performed by Radoslaw 
Kowalczyk at the University of Reading) to be 924.1. In this work, weighed amounts of AmB 
were dissolved in ultrapure water from a Barnstead Nanopure system to the desired 
concentration. pH was then adjusted to 12 through addition of NaOH from Fisher Scientific 
(USA), dissolved pellets in water to give a 5M solution.  
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5.2.1 Pyrene fluorescence 
Fluorescence spectra were recorded with a Varian Cary Eclipse Fluorescence Spectrometer 
with samples in 4 mm inner Quartz cuvettes. The assays were performed using 1.3x10-3 – 0.13 
wt% AmB, in 2.3 x 10-5 wt% pyrene solution. The samples were excited at λex=380 nm, and the 
fluorescence emission was measured for λ= (400-550nm).  
 
5.2.2 Cryo-TEM 
Experiments were carried out by our collaborators at Aalto University in Finland using a field 
emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. Images were 
taken using bright-field mode and zero loss energy filtering (omega type) with a slit with 20 eV. 
Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The specimen 
temperature was maintained at -187 °C during the imaging. Vitrified specimens were prepared 
using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids with 
3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma cleaner just prior to 
use and then transferred into an environmental chamber of FEI Vitrobot at room temperature 
and 100% humidity. Thereafter, 3 μl of sample solution at 1 wt% concentration was applied on 
the grid, blotted once for 1 second and then vitrified in a 1/1 mixture of liquid ethane and 
propane at -180 °C. Grids with vitrified sample solutions were maintained in a liquid nitrogen 
atmosphere and then cryo-transferred into the microscope. 
 
5.2.3 Small-angle X-ray scattering (SAXS) 
Experiments were performed on beamline ID02 at the ESRF (Grenoble, France). Samples were 
placed in a glass capillary mounted in a brass block for temperature control. Micropumping 
was used to minimise beam damage by displacing a drop of the sample by 0.01 - 0.1 mm for 
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each exposure. The sample-to-detector distance was 2 m, and the X-ray energy was 12.46 keV. 
The q = 4π sin θ/λ range was calibrated using silver behenate. Data processing (background 
subtraction, radial averaging) was performed using the software SAXSutilities.  
 
5.2.4 Circular Dichroism (CD) 
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK). 
The sample (0.01 - 1 wt% in water, pH raised to 12 with NaOH) was placed in a cover slip 
cuvette (0.1 mm thick). Spectra are presented with absorbance A < 2 at any measured point 
with a 0.5 nm step, 1 nm bandwidth, and 1 second collection time per step at 20 C. In 
temperature-dependent experiments, the AmB solution was acclimatised at each temperature 
point for 5 minutes before measurements were taken. The CD signal from the pH 12 alkalised 
water was subtracted from the CD data of the AmB solution. 
 
5.2.5 Fourier transform infrared spectroscopy (FTIR) 
For the secondary structure studies, spectra were recorded using a Thermo Scientific Nicolet 
IS5 and a Nexus-FTIR spectrometer, both equipped with a DTGS detector. A 40 μL drop of the 
sample (in D2O with pH raised to 12) was sandwiched between two CaF2 plate windows, with a 
0.006 mm thick Mylar spacer) in a Specac GS20500 sample cell holder. Spectra were scanned 
128 times over the range of 900–4000 cm–1. 
 
5.2.6 Two-photon fluorescence lifetime imaging 
Two-photon-induced fluorescence lifetime images were obtained with multiphoton 
microscopy apparatus constructed on an Eclipse TE2000 (Nikon) with Becker and Hickl 
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confocal scanning (DCS120) capability FLIM. Briefly, a high-powered titanium sapphire laser 
(MIRA 900; Coherent Lasers) was pumped by a frequency-doubled neodymium:vanadate laser 
(Verdi V10; Coherent Lasers, UK) to produce a 700-930 nm  laser light of 180-fs pulses at 76 
MHz. Specimens on a Nikon TE2000U microscope stage were excited by focusing the near-
infrared laser beam to a diffraction-limited spot through a 60× water immersion objective 
(numerical aperture [NA], 1.2). Fluorescence emissions from specimens were collected, 
bypassing the scanning system, through a band-pass filter (BG39, Comar) using a non-
descanned port of the confocal microscope. Single-photon pulses were detected by an 
external fast microchannel plate photomultiplier tube (Hammamatsu R3809U). The scan, 
which was operated in a normal mode and line, frame, and pixel clock signals were 
synchronized and collected with a time-correlated single-photon-counting (TCSPC) PC module 
(SPC-830; Becker and Hickl, Germany). 
 
5.3 Results and discussion 
The critical aggregation concentration (cac) of AmB was determined using pyrene, as with the 
other compounds mentioned in some previous chapters. Interestingly, it was found that with 
increasing concentration of AmB, the already low pyrene fluorescence peak at 373 nm 
compared with previous pyrene fluorescence experiments, decreased. This is shown in figure 
3a. Conversely, increasing concentration eventually lead to an increase of peak at 475 nm, 
which is usually seen in pyrene fluorescence assays at 373 nm. The reason for this is so far 
unknown, although similar emission spectra have been noted previously with AmB [19]. The 
intersection of the two lines showing this point, shown in figure 3b, was used as the critical 
aggregation point, found to be 0.06 wt% (± 0.01 wt%). 
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The self-assembly of AmB was investigated through the use of cryo-TEM and SAXS. Cryo-TEM 
has previously only been used to observe AmB when in lipid or surfactant-based particle 
systems [20, 21]. The cryo-TEM images in figure 4 reveal a mixture of mostly cylindrical 
micelles of varying lengths, but also very long twisting tape-like structures in a) and b). The 
diameters of the cylindrical micelles were measured at around 5 nm, which was also 
confirmed in the SAXS fitting profile (figure 5). The fit used a long cylindrical shell form factor, 
a scaling factor of 0.03, diameter 6.7 nm, shell thickness 2.2 nm, solvent side bilayer thickness 
of 0.28 nm, inner bilayer thickness of 1.2 nm, and scattering length densities of solvent, 
solvent side bilayer, and inner bilayer of 0.00033-0.00068 nm, and background parameter of 
0.00034. 
 
 
 
 
Figure 3 Fluorescence assay of amphotericin B using pyrene. a) Shows the spectra of each 
concentration across the range used, b) shows the intensity of each concentration at the 
peak value at 475 nm, with cac indicated at the intersection of the lines. 
a b 
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b a 
c 
Figure 4 Representative cryo-TEM images of 1 wt% amphotericin B.  
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The secondary structure was investigated firstly through CD spectroscopy in water alkalised to 
pH 12, which it has been suggested favours AmB dimerization at lower concentrations [22]. At 
20°C, results, shown in figure 6, showed a similar shaped spectrum to that previously 
attributed to the aggregated form whilst in PBS, shown in figure 8 [14]. This consisted of a 
series of small descending negative peaks at 422, 392 and 372 nm, followed by a large positive 
peak at 336 nm. This spectrum has also been observed a number of other times with AmB [22-
24]. However, this developed into a different spectrum, with a transition around 30°C, shown 
by the inclusion of two successive scans at 30°C. Upon heating, the spectrum shape changes to 
one with a pronounced negative peak at 326 nm, which to our knowledge has not seen with 
AmB before. This therefore was ascribed to the novel AmB structures seen in the cryo-TEM 
images in figure 4. The next set of experiments further explored this, leaving the 0.1 wt% AmB 
Figure 5 SAXS data (black symbols) with model form factor (red line) of a 0.1 wt% solution of 
amphotericin B. Specific dimensions for the fit are described in the text.   
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sample at the same temperature, with CD signal measured at various time points (figure 7a), 
which showed a similar starting spectrum shape and progression to the spectrum with 
minimum at 326 nm shown in figure 6. The absorbance spectrum (figure 7b) is comparable 
with that seen in figure 8, but with AmB in DMSO and alkalised water, attributed to a 
monomeric form. This consists of three peaks, which are retained over the 24 hours, along 
with the development of another small peak at 326 nm. This correlates with the large 
minimum seen in the CD spectrum in figure 7a. A time-dependent change had also been 
observed by the Starzyk group [14]. A hypothesis was proposed that the UV light emitted from 
the CD machine during experimentation was causing cross-linking within the polyene 
backbone.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Temperature-dependent CD spectrum of 0.1 wt% solution of amphotericin B, with 
observed transition when measured twice at 30°C. 
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Figure 7 a) Time-dependent CD spectrum of 0.1 wt% solution of amphotericin B 
at 20°C, b) corresponding absorbance spectrum. 
a b 
Figure 8 Absorption (red) and CD (black) spectra of AmB in various solutions by the Starzyk 
group [14]. 
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This was tested through FTIR experimentation, which does not emit UV light, but still reveals 
information about secondary structure. Shown in figure 9, there is also a change observed 
over time. There is a very large broad peak seen which stretches from ~3100-3600 cm-1. This 
can be attributed to O-H stretch bonds, which have been shown to give large broad peaks in 
this area, along with amine stretch [25]. The peak is clearly shown to increase in absorbance 
relative to time, and shows no sign of plateauing, even at the latest time point at 72 hours. 
Due to time constraints on the CD experiments, it could not be seen whether the negative 
peak continued to increase (figure 7a) as the FTIR one had. The fact these changes occur 
during FTIR experimentation implies that these changes seen using CD in figure 6 and 7a are 
not due to UV exposure.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Time-dependent FTIR spectrum of 0.1 wt% solution of amphotericin B at 20°C. 
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With evidence that the changes in structure were not temperature-dependent, and that UV 
exposure was not the cause, a hypothesis was proposed that the time taken between the 
preparation of the sample and the measurements was responsible. Work to test this was not 
carried out due to the lack of time, but is a new area of interest and can be explored in future 
work. It has previously been seen with AmB that auto-oxidation can occur in some cases [26, 
27]. Mass spec and 1H and 13C NMR, performed by collaborator Radoslaw M. Kovalczyk at the 
University of Reading, were therefore undertaken on aged samples of the compound. These 
results are shown in the supplementary information of the published paper [187] and revealed 
no evidence of any molecular degradation or auto-oxidation.  
As part of some preliminary measurements, AmB was investigated through fluorescence 
lifetime imaging microscopy (FLIM). It has previously been proposed that AmB can be present 
in different forms, both a parallel and antiparallel dimer, based on the observed differing 
lifetimes [14]. In these experiments, the same concentration was used, but in different 
solvents, DMSO and alkalised water, and with different excitation wavelengths. Two-photon 
excitation was used in this case in order to access UV wavelengths more easily than with 
single-photon excitation through a microscope set up (future studies aimed to include imaging 
AmB in live cells, but weren’t able to be completed due to time constraints). The excited state 
decay curves obtained were best fitted using two exponential components. Figure 10 shows 
that the lifetime in the first component is unchanged by the differing excitation wavelengths in 
both water and DMSO. The second component however shows a large change in lifetime in 
the two solvents when excited at different wavelengths. These two components are likely due 
to different energy states in the molecule. This raises questions about the claim from the 
authors of ref [14] of AmB being present in different forms shown by the fluorescence 
lifetime-associated spectra, as merely changing the excitation wavelength here has been 
shown to give different lifetime values that are not too dissimilar to those reported in ref [14], 
but with concentration change. The motivation for using different excitation wavelength stems 
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from the features in the absorption spectra. Originally, the wavelength started with was the 
same as the authors in reference [14], but it was soon realised that 810 nm wasn’t the 
maximum excitation, particularly when using multiphoton excitation.  
 
 
 
 
 
 
 
 
 
 
 
In this chapter, a number of techniques were used to determine the self-assembling of 
properties of AmB in water alkalised to pH12. As the structures which the drug is able to form 
have been linked with toxicity in patients [14, 29, 30], this research can have important 
information in helping reduce the toxicity. At the concentrations we have used, it seems AmB 
forms aggregated structures, with the suggestion that they can change over time to give even 
larger aggregations in different forms. In contrast to previous studies [14], these changes seem 
to not merely lead to shifted spectra which retain their structure, but completely different 
assemblies with very large intensities. We have also proven that, unlike some earlier 
Figure 10 Two-photon excitation FLIM data of amphotericin B at various excitation 
wavelengths showing first and second components.  
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hypotheses, these changes are not specifically due to temperature, nor are they UV light-
induced. It was only proposed later on in the research that the length of time between the 
preparation of the samples, and then the use of them in experiments, could have an effect on 
what structure it is present in.  
Further cryo-TEM images to compare a freshly prepared sample with an older one/one which 
has been heated and cooled again may provide interesting results, to observe whether these 
changes in CD signal are reflected in a changing structure. The long tape-like structures were 
seen in the cryo-TEM images, but the SAXS profile was fitted to a form factor for the cylindrical 
micelles. These structures were much more abundant, and it may be that the tape-like 
structures were too few to contribute to the SAXS profile.  Cryo-TEM was at 1 wt%, and SAXS 
at 0.1 wt%, therefore there is also the possibility that the structures may only be a product of 
the higher concentration. Uniformity across different experiment types, so that direct 
conclusions may be made, would therefore be beneficial.   
Previously it has been proposed, through the use of FLIM, that AmB at concentrations below 
our determined cac (0.00085 wt%, versus 0.1-1 wt% in this chapter) is present in two different 
dimer forms, parallel and antiparallel [22]. Our FLIM data, at concentrations above our 
experimentally determined cac, suggest that further research is needed to understand the 
wavelength-dependent intensities. Due to time constraints, these extra FLIM experiments 
weren’t able to be done. However, if indeed the previous model [14] is correct and AmB is 
present in the two forms, it may also give information on why two different CD spectra have 
been seen.  
The presence of two aggregated forms of AmB could have interesting implications in the 
pursuit of reducing toxicity. As previously referred to, it has been suggested that an AmB 
aggregate is responsible for the more recently found mechanism of action upon binding 
ergosterol, which then forms the transmembrane channel [31]. Further work into comparisons 
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of the types of aggregates formed under different conditions would be interesting. Use of 
liposomes to mimic lipid bilayers, and other solvents which better resemble the physiological 
environment of the body, would shed more light on whether these new aggregated structures 
are responsible for the toxic effects of the drug.  
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Chapter 6 - Self-assembly of daptomycin, and comparison with and 
without calcium chloride 
 
6.1 Introduction 
Daptomycin is a cyclic lipopeptide drug active against gram-positive bacteria, produced by the 
gram-positive bacterium Streptomyces roseosporus [1]. The drug is also effective against 
bacteria resistant to other drugs, such as methicillin-resistant Staphylococcus aureus (MRSA) 
and vancomycin-resistant Enterococcus (VRE) [2]. It is also known under its trade name Cubicin 
[3]. As shown in figure 1, it is composed of 13 amino acids, 10 making up the cyclic structure 
and the other 3 forming a chain. The cyclic section of the molecule is linked through an ester 
bond to the tail through the terminal kynurenine, an amino acid product of tryptophan 
metabolism only observed in daptomycin, and the threonine hydroxyl group [3]. The 
kynurenine residue, specifically the aniline component contained within, is also responsible for 
a fluorescence emission peak at 460 nm [4]. Another emission peak at 355 nm is due to Trp-1 
[4].  
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Daptomycin’s concentration-dependent [5] mechanism of action has not been fully elucidated. 
One hypothesis was that inhibition of lipoteichoic acid (LTA) biosynthesis was responsible for 
daptomycin’s antibiotic activity [6, 7]. However, more recent studies have shown a continued 
bactericidal activity in the absence of LTA synthesis [8]. The more favoured hypothesised 
mechanism is believed to involve disruption of the bacterial cell membrane by insertion of the 
daptomycin lipophilic N-terminal decanoyl chain into the membrane [9]. This then allows the 
flow of potassium ions out of the cell, and sodium influx [10], which causes depolarisation of 
the membrane, and is proposed to be the cause of cell death [11]. Daptomycin itself is able to 
cause this effect despite both it and the bacterial membrane being negatively charged. This is 
believed to be due to the presence of cations, in particular calcium ions, said to be vital for its 
antibiotic activity [12, 13]. These ions are believed to cause deeper penetration into the 
membrane due to the bridging of residual negative amino acids and negative phospholipids in 
the bacterial cell membrane [14]. There is also the possibility of further contribution towards 
cell death from oligomerization in the membrane in the presence of calcium ions, causing 
Figure 1 Molecular structure of daptomycin. Trp = tryptophan, Asn = asparagine, Asp = 
aspartic acid, Thr = threonine, Gly = glycine, Orn = ornithine, D-Ala = D-Alanine, D-Ser = D-
Serine, MeGlu = methylglutamic acid, Kyn = kynurenine. 
Trp 
Asn 
Asp 
Kyn 
Thr 
MeGlu 
D-Ser 
Gly 
Asp 
D-Ala 
Asp 
Orn 
Gly 
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disruption of cell membrane development when the oligomer dissociates at the bacterial 
membrane [15]. This antibacterial process is calcium-dependent, although the reasons are 
poorly understood. Daptomycin has also been shown to cause the inhibition of various cellular 
processes, including synthesis of proteins, DNA and RNA [16]. 
It has been reported that a 1:1 ratio of Ca2+ to daptomycin leads to micelle formation, 
although this does not lead to a change in the daptomycin conformation [17]. In the absence 
of calcium ions, one of three forms of daptomycin have been proposed, none of which are 
highly amphiphilic [15]. At a molar equivalent of added Ca2+ ions, it is proposed, based on NMR 
experiments, that 14-16 daptomycin monomers oligomerize, likely into a micelle [18]. Calcium 
ions are thought to bind between two of the aspartic acid residues on the daptomycin 
molecule, decreasing its net charge and increasing its hydrophobic area, allowing it to better 
interact with membranes [14]. When the oligomer is in close proximity to the bacterial 
membrane, it dissociates and the insertion process described above occurs.   
Despite this prior work, there is no direct evidence for the nature of the self-assembled 
structures of daptomycin. This was therefore the aim set out for this chapter, with 
experiments performed both in the presence and absence of calcium ions. The ratios of 
daptomycin to CaCl2 chosen and the use of 100 mM KCl solutions were selected based on 
previous reports [15, 17, 18].  
 
6.2 Materials & Methods 
Daptomycin was obtained from Merck Millipore (USA) with a molecular weight of 1620.7 
g/mol and a purity of 100% determined by HPLC. Potassium chloride was from Fisher Scientific 
(UK) and calcium chloride from Sigma-Aldrich (USA). All samples were prepared in 100 mM 
KCl, based on previous literature [15, 17-19], unless otherwise mentioned.  
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6.2.1 Fluorescence Assays 
Fluorescence spectra were recorded with a Varian Cary Eclipse Fluorescence Spectrometer 
with samples in 4 mm inner Quartz cuvettes. The assays were performed using 1.3x10-3 – 0.13 
wt% daptomycin solutions in 100 mM KCl. The samples were excited at λex=380 nm, and the 
fluorescence emission was measured for λ= (400-550nm).  
 
6.2.2 Cryo-Transmission electron microscopy (cryo-TEM) 
Experiments were carried out by our collaborators at the University of Aalto, Finland using a 
field emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. Images were 
taken using bright-field mode and zero loss energy filtering (omega type) with a slit with 20 eV. 
Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The specimen 
temperature was maintained at -187 °C during the imaging. Vitrified specimens were prepared 
using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids with 
3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma cleaner just prior to 
use and then transferred into an environmental chamber of FEI Vitrobot at room temperature 
and 100% humidity. Thereafter, 3 μl of sample solution at 0.5 wt% in 100 mM KCl was applied 
on the grid, blotted once for 1 second and then vitrified in a 1/1 mixture of liquid ethane and 
propane at -180 °C. Grids with vitrified sample solutions were maintained in a liquid nitrogen 
atmosphere and then cryo-transferred into the microscope. 
 
6.2.3 Circular Dichroism (CD)  
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK). 
Each sample (0.1 wt% daptomycin in 100 mM KCl and with 0 mM, 0.154 mM or 0.625 mM 
CaCl2) was placed in a cover slip cuvette (0.1 mm thick). Spectra are presented with 
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absorbance A < 2 at any measured point with a 0.5 nm step, 1 nm bandwidth, and 1 second 
collection time per step at 20 C. Each daptomycin solution was acclimatised at each 
temperature point for 10 minutes before measurements were taken. The CD signal from the 
background was subtracted from the CD data of the daptomycin solution. 
 
6.2.4 Small-Angle X-ray Scattering (SAXS) 
Experiments were performed on beamline B21 at the Diamond Light Source, Harwell, UK. 
Solutions of daptomycin (0.5, 1 and 2 wt% with 100 mm KCl and with or without CaCl2) were 
loaded into the 96 well plate of an EMBL BioSAXS robot. Aliquots of solutions (25 μL) were 
then injected via an automated sample exchanger at a slow and very reproducible flux into a 
quartz capillary (1.8 mm internal diameter) in the X-ray beam. The quartz capillary was 
enclosed in a vacuum chamber to avoid parasitic scattering. After the sample was injected in 
the capillary and reached the X-ray beam, the flow was stopped during the SAXS data 
acquisition. SAXS frames were collected with a duration of 20 or 100 s. B21 operated with a 
fixed camera length (4.01 m) and fixed energy (12.4 keV). The images were captured using a 
Pilatus 2m detector. Data processing (background subtraction, radial averaging) was 
performed using the dedicated beamline software Scatter. 
 
6.2.5 Fourier transform infrared spectroscopy (FTIR) 
Spectra were recorded using a Thermo Scientific Nicolet IS5 and a Nexus-FTIR spectrometer, 
both equipped with a DTGS detector. A 40 µl drop of the sample (6.17 mM daptomycin in 100 
mM KCl with or without 1.54 mM or 6.17 mM CaCl2 in D2O) was sandwiched between two CaF2 
plate windows, with a 0.006 mm thick Mylar spacer) in a Specac GS20500 sample cell holder. 
Cells were heated using a Specac 4000 series high stability heating controller, and a Specac 
electrical heating jacket. The sample was acclimatised at each temperature point for 10 
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minutes before measurements were taken. Spectra were scanned 128 times over the range of 
900-4000 cm-1.  
 
6.3 Results and discussion 
Firstly, the concentration at which daptomycin aggregates (the critical aggregation 
concentration, cac) was found through fluorescence assay. This was based on the self-
fluorescence peak at 466 nm, similar to the 460 nm peak described in the introduction, rather 
than the usual method of using pyrene. The spectra are shown in figure 2. Figure 3 compares 
the cac of daptomycin in salt-free solution, and with molar ratios of 4:1 and 1:1 CaCl2 added 
(based on previous reports [18]). The cac was found to be 0.02 wt%, with an error of 0.003 
wt%, with no discernible differences between the three different solution types. This value of 
0.02 wt% also correlates with another previously reported value through daptomycin auto 
fluorescence, in this case without CaCl2, using dynamic light scattering at pH4 (0.02 wt% in this 
case is equal to the 0.12 mM quoted in the reference) [4]. 
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a b 
c 
Figure 2 Fluorescence emission spectra for daptomycin solutions at various concentrations in 
100 mM KCl. a) daptomycin with no CaCl2, b) with a daptomycin : CaCl2 ratio of 4:1, and c) 
daptomycin : CaCl2 ratio of 1:1. 
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The secondary structure of daptomycin was investigated through the use of CD and FTIR, both 
in the presence and absence of CaCl2, above the measured cac. Figure 4 shows CD spectra of 
daptomycin on its own, along with two solutions with the molar ratio to CaCl2 as seen in the 
cac measurements at room temperature, and Figure 5 shows CD spectra taken over a range of 
successive temperatures. As with the cac measurements, there is no systematic difference 
seen between any of the spectra for a given sample as a function of temperature. The spectra 
are similar to those that have been seen before in the literature with daptomycin with CaCl2 
[17], including the very broad peak around 360 nm, as well as the prominent maximum peak 
around 231 nm. In this paper, the latter peak shifted from 233 nm to 231 nm upon addition of 
CaCl2, a change which was not observed in these experiments. The solution containing a 1:1 
ratio of daptomycin to CaCl2 did cause an increase in the maximum of the peak when 
Figure 3 Critical aggregation concentration of daptomycin using the self-fluorescing emission 
peak at 466 nm, with cac indicated by the intersection of the lines. Daptomycin ratios are 
presented as a molar ratio between daptomycin and CaCl2.  
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compared with daptomycin without CaCl2. A 4:1 ratio however causes the peak to become 
negative. Changes in the spectra around 231 nm have previously been associated with the 
presence of Trp [20], and so the peak seen in these experiments can tentatively be applied to 
this. The peak at 258 nm has previously been seen with absorption spectra of daptomycin and 
kynurenine, as well as the aforementioned broad peak around 360 nm [4,13].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 CD spectra for 0.1 wt% daptomycin solutions in 100 mM KCl with daptomycin to 
CaCl2 ratios indicated. 
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Figure 6 shows the FTIR spectra for all three solutions tested. The spectra for the three are 
very similar in the range of 1250-2000 cm-1. The peak at 1454 cm-1 can be assigned to HDO 
stretching deformations, which is formed through H/D exchange between protons and D2O 
[21]. However, this peak could also be due to a Trp side group deformation [22, 23]. The peak 
at 1648 cm-1, in the amide I’ band, is indicative of an unordered peptide conformation [22, 24], 
and the shoulder peak at 1720 cm-1 attached to it is assigned to carbonyl stretch [25]. The 
intensity of the broad peak at 3400 cm-1 is the only peak which significantly differs between 
the three spectra. Daptomycin with no CaCl2 shows a very low intensity peak, followed by the 
Figure 5 CD spectra for 0.1 wt% daptomycin solutions in 100 mM KCl with daptomycin to 
CaCl2 ratios of a) 1:1, b) 4:1, c) no CaCl2. 
a b 
c 
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4:1 daptomycin to CaCl2 solution having a more pronounced peak, and the 1:1 solution giving 
the highest intensity. This peak is assigned to –OH stretch vibrations [25]. The increased 
intensity of the peak in CaCl2-containing solutions could be caused by the increased 
stabilisation of H-bonding between daptomycin molecules in the presence of salt. 
 
 
 
 
 
 
 
 
 
 
 
 
Cryo-TEM images of daptomycin both in the presence and absence of CaCl2 were obtained 
from our collaborators in Finland. Figure 7 reveals the presence of spherical micelles from all 
three different solutions, with the structures estimated to have a diameter of around 5 nm. 
This correlates with the lack of secondary structure seen in both the CD and FTIR results. This 
Figure 6 FTIR spectra for 1 wt% daptomycin solutions in 100 mM KCl solutions in D2O. 
Daptomycin ratios are presented as a molar ratio between daptomycin and CaCl2. 
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lack of secondary structure combined with micelle formation has also been seen in the 
previous chapter [26], as well as in other papers by colleagues in our group [27].  
 
 
 
 
 
 
 
 
 
 
 
 
SAXS was then used in order to determine the specific structural parameters and dimensions 
of the micelles. The data were fitted to a core-shell sphere model, with the data and fit of 
daptomycin with CaCl2 shown in figure 8a, and without CaCl2 in figure 8b. It was found that, 
despite changes in concentration and the presence/absence of CaCl2, the radius of the 
micelles stayed constant at a radius of 27.2 Å with an error of 0.1 Å. The only parameters 
which changed included the scattering contrast of the shell and core, and the inner radius of 
the core. This is particularly shown at 2 wt% where the inner core radius value is higher and 
Figure 7 Representative cryo-TEM images of 0.5 wt% daptomycin solutions (a) and b)), with 
daptomycin:CaCl2 ratio of 4:1 (in c) and d)), and 1:1 (in e) and f)). 
a c e 
b d f 
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the relative scattering contrast of the inner core is lower, which is indicative of an increased 
packing of hydrophobic units owing to these units having a negative scattering density relative 
to the solvent. The full list of specific parameters is presented in table 1 and 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 SAXS data of a range of concentrations of a) 1 wt% daptomycin with a 4:1 molar 
ratio with CaCl2, b) 1 wt% daptomycin with no CaCl2 present.   
a b 
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Table 1 Fitting parameters for SAXS data using a core-shell sphere form factor. 1 wt% 
daptomycin 4:1 molar ratio to CaCl2 (corresponding to figure 8a). Courtesy of I.W. Hamley. 
Daptomycin 
wt% 
Na (x10-
9) 
σb Roc (Å) Rid (Å) μe ηf Background 
(x10-4) 
0.5 2.06 2.08 27.21 7.61 -2.49 0.04 3.2 
1 2.88 2.54 27.27 7.61 -2.98 0.05 3.5 
2 5.11 2.9 27.1 7.39 -3.74 0.05 4.8 
 
Table 2 Fitting parameters for SAXS data using a core-shell sphere form factor. 1 wt% 
daptomycin (corresponding to figure 8b). Courtesy of I.W. Hamley.  
Daptomycin 
wt% 
Na (x10-
9) 
σb Roc (Å) Rid (Å) μe ηf Background 
(x10-4) 
0.5 0.90 2.08* 27.21* 7.61* -2.49* 0.05 1.1 
1 1.72 2.54* 27.27* 7.61* -2.98* 0.05 1.6 
2 4.11 2.9* 27.1* 7.39* -3.74* 0.05 0.25 
 
SAXS form factor model fitting parameter definitions: 
a = Scale factor 
b = Gaussian polydispersity (of outer radius) parameter 
c = outer radius 
d = inner radius 
e = scattering contrast of inner core 
f = scattering contrast of shell 
* = value constrained based on fits in table 1 
 
In this chapter the self-assembly of daptomycin was explored, with two different molar ratios 
of the compound to CaCl2, as well as in the absence of CaCl2. Up to a molar ratio of 1:1, used in 
previous literature, we have shown that, in contrast to findings reported previously [15, 18, 
28, 29], CaCl2 is not required in order for daptomycin to self-assemble into micelles. Prior 
publications [15] have claimed that a 1:1 molar ratio of daptomycin : CaCl2, one of the ratios 
also used in this research, is required in order for daptomycin to oligomerize into a micelle, 
consisting of 14-16 daptomycin monomers. This self-assembly has been characterised to show 
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formation of spherical micelles, largely unchanged in dimension with daptomycin 
concentration or addition of CaCl2 up to a 1:1 molar equivalent. Molecular dynamics 
simulations by another group have also shown no dependence on calcium ions for 
micellization [30]. As they summarise at the end of the report, this implies that the role of 
calcium ions in daptomycin’s mechanism of action is either in binding, membrane entry or 
stabilisation in the membrane, and not in its aggregation.  
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Chapter 7 - Self-assembly of custom-synthesised telechelic conjugates 
with PEO/poly(alanine) central blocks 
 
7.1 Introduction 
The combining of peptides with polymers in order to enable both components’ properties is 
an interesting area of research in the production of biomaterials and can be used in a wide 
range of applications [1]. Polymer-peptide conjugates can be designed either to synergistically 
combine the two component properties when linked together, or to compensate for 
disadvantages one component may possess [2]. Addition of synthetic polymers to peptides has 
been shown to improve the stability, solubility and biocompatibility of the combined 
compound [3, 4], among other factors [5, 6]. From this, biomaterials with a range of 
applications in the medical, biotechnological and nanotechnological areas can be derived [1]. 
Based on these interesting characteristics, three samples were custom synthesised by a 
collaborator at the University of Athens, Greece, consisting of a central block polymer with 
short tyrosine end caps. Two of these had a central block consisting of polyethylene 
oxide/polyethylene glycol (PEO/PEG), but with different molar masses; 2000 g mol-1 and 6000 
g mol-1. Both were capped at each end of the chain by pentameric tyrosine sequences. The 
other compound had a central block of poly(alanine), estimated to be 64 repeats, and trimeric 
tyrosine sequences capping either end.  
The custom-synthesised compounds used in this research also possess another interesting 
dimension through their hydrophobic-hydrophilic-hydrophobic triblock sequence. There are a 
number of hydrophobicity scales for determining the classification of amino acids [7-11], 
which in general state tyrosine as being hydrophobic, and alanine as hydrophilic. Compounds 
with this triblock sequence are used in associating polymers, which are polymers with a small 
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number of hydrophobic groups attached to either side of the polymer backbone. This enables 
self-association in aqueous solution to reduce exposure to the solvent, similarly to micelles 
[12]. The rheological properties of associative polymers, specifically over the past five years, 
has been reviewed extensively elsewhere [13]. Briefly, these associative polymers are able to 
provide useful properties, including increased viscosity, gelation and shear-thinning and 
thickening. An example of associative polymers are reverse Pluronics, a type of reverse 
poloxamer which have a hydrophobic-hydrophilic-hydrophobic amphiphilic sequence through  
the copolymers PEO (hydrophilic) and poly(propylene oxide) (PPO) (hydrophobic) [14].  
The compounds used in this work also present an interesting area as there is currently little 
research into the self-assembled properties of telechelic polymers. These are defined as 
polymers with the same reactive end groups on either side of a central block, able to further 
polymerise or enter into other reactions [15]. In the case of the three custom-synthesised 
polymers, these reactive groups are the tyrosine end-caps, although no reactions with tyrosine 
were performed in this research. Telechelic polymers have been reported to form networks 
when in high concentration, connected through PEO chains, and flower-like micelles at lower 
concentration, where both end groups arrange to become part of the hydrophobic core [16]. 
The Hamley group have investigated a similar compound consisting of a 1500 g mol-1 PEO 
centre block, capped with differing hydrophobic dipeptides [17]. When tyrosine dipeptides 
were present, β-sheet fibrillar structures were formed, which contrasted with those seen with 
diphenyl end caps which didn’t show β-sheet formation. The tyrosine end-capped telechelic 
polymer was also shown to undergo a transition at 37 °C (physiologically relevant as it 
correlates with body temperature) causing a melting of the hydrogel. Another group used a 
PEO centre block of 3000 g mol-1 end-capped by desaminotyrosine (DAT) and 
desaminotyrosyltyrosine (DATT) [18], which were shown to display surfactant-like properties. 
Another triblock copolymer comprised of PEO with poly(L-leucine) end caps with a total 
molecular weight of 3500 Da was investigated [19]. It was found to self-assemble into micelles 
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with the peptide adopting an α-helical conformation which was shown to make it a good 
candidate as a delivery system for hydrophobic drugs.  
Polymer-peptide conjugates can be used as novel materials in the creation of hydrogels 
(defined as a water phase immobilised by a scaffold [20]), in applications such as drug delivery 
[21, 22] and as artificial extracellular matrices (ECM) [23]. The hydrogel becomes the 
framework whereby reservoirs are present which components such as drugs can be released 
from [24]. Alginates are polysaccharides which are isolated from brown algae [25], commonly 
used in cell culturing experiments and which are relatively inexpensive [26-28]. When it was 
found later in the project that the compounds were unable to form a gel at higher 
concentrations in order to introduce to the cells on their own, incorporation of them into an 
alginate gel was proposed. The tyrosine component of the compounds represented an 
interesting area of research. Tyrosine kinases and phosphorylases, enzymes which add and 
remove phosphate groups respectively, affect upon tyrosine and are involved in many cellular 
processes [29]. 
 
7.2 Materials & Methods 
Synthesis was performed in the group of Hermis Iatrou at the University of Athens, Greece, 
and can be found in full detail in the published paper [30].  
 
7.2.1 NMR and FTIR Spectroscopy 
1H NMR spectroscopy (300 MHz) was performed by collaborators at the University of Reading 
using a Varian Unity Plus 300/54 spectrometer. The spectra of the polymers were measured 
either in deuterated DMSO (NCA and poly(L-tyrosine)-PEO-poly(L-tyrosine)) or in CF3COOD (the 
Tyr3-PAla-Tyr3 copolypeptide). FTIR measurements were also performed by collaborators at 
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the University of Reading with a PerkinElmer Spectrum One instrument, in KBr pellets at room 
temperature, with spectra being recorded over the range 450–4000 cm–1. 
 
7.2.2 Sample Preparation 
The solubility of samples dissolved into water was found to be poor, but pH adjustment to 12 
(above the pKa of tyrosine [31]) using an NaOH solution led to satisfactory solubility. Therefore 
this was the pH value selected for all measurements for samples Tyr5-PEO2k-Tyr5 and Tyr3-
PAla-Tyr3. Since sample Tyr5-PEO6k-Tyr5 was found to show good solubility in water, it was 
also studied at its native pH, pH 5.69. 
 
7.2.3 Circular Dichroism (CD)  
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, UK) in 
the wavelength range 190–320 nm. The samples, 0.5 wt% in water raised to pH 12 or native 
pH for Tyr5-PEO6K-Tyr5, were placed in a coverslip cuvette (0.1 mm thick), with spectra 
presented with absorbance A < 2 at any measured point with a 0.5 nm step, 1 nm bandwidth, 
and 1 s collection time per step. Samples were acclimatized at each increasing 10 °C 
temperature point for 5 min, and 30 min for the 60–20 °C change, before measurements were 
taken. The CD signal from the background was subtracted from the CD spectra of the sample 
solutions. 
 
7.2.4 Fourier transform infrared spectroscopy (FTIR) 
Spectra were recorded using a Thermo Scientific Nicolet IS5 and a Nexus-FTIR spectrometer, 
both equipped with a DTGS detector. A 40 μL drop of the sample (in D2O) was sandwiched 
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between two CaF2 plate windows, with a 0.006 mm thick Mylar spacer in a Specac GS20500 
sample cell holder. Spectra were scanned 128 times over the range of 900–4000 cm–1. 
 
7.2.5 X-ray Diffraction (XRD) 
X-ray diffraction was performed on a peptide stalk prepared by drawing a fiber of 1 wt% 
conjugate solution between the ends of wax-coated capillaries. After separation and drying a 
stalk was left on the end of one capillary. For some samples, the capillary was mounted 
vertically onto the four axis goniometer of a RAXIS IV++ X-ray diffractometer (Rigaku) 
equipped with a rotating anode generator (CuKα radiation, wavelength λ = 1.54 Å). The XRD 
data was collected using a Saturn 992 CCD camera. The sample-to-detector distance was 50 
mm. Other measurements were performed on stalks mounted (vertically) onto the 
goniometer of an Oxford Instruments Gemini X-ray diffractometer, equipped with a Sapphire 3 
CCD detector. The sample to detector distance was 45 mm. 
 
7.2.6 Cryo-Transmission electron microscopy (cryo-TEM) 
Experiments were carried out by our collaborators at the University of Aalto, Finland using a 
field emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. Images were 
taken using bright-field mode and zero loss energy filtering (omega type) with a slit with 20 eV. 
Micrographs were recorded using a Gatan UltraScan 4000 CCD camera. The specimen 
temperature was maintained at -187 °C during the imaging. Vitrified specimens were prepared 
using an automated FEI Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids with 
3.5 μm hole sizes. Grids were cleaned using a Gatan Solarus 9500 plasma cleaner just prior to 
use and then transferred into an environmental chamber of FEI Vitrobot at room temperature 
and 100% humidity. Thereafter, 3 μl of each sample solution at 1 wt% was applied on the grid, 
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blotted once for 1 second and then vitrified in a 1/1 mixture of liquid ethane and propane at -
180 °C. Grids with vitrified sample solutions were maintained in a liquid nitrogen atmosphere 
and then cryo-transferred into the microscope. 
 
7.2.7 Small-Angle X-ray Scattering (SAXS) 
For the solutions, experiments were performed on ID02 at the ESRF, Grenoble France. Samples 
were flowed through a quartz capillary. After the sample was injected in the capillary and 
reached the X-ray beam, the flow was stopped during the SAXS data acquisition. The sample–
detector distance was 2 m (data were also obtained at 10 m). Data processing (background 
subtraction, radial averaging) was performed using the dedicated beamline software or 
SAXSutilities. 
 
7.2.8 Alginate hydrogel protocol 
As briefly mentioned in the introduction, the three custom-synthesised compounds were 
unable to form gels at high concentrations. Alginate hydrogels were therefore produced to 
incorporate the compounds into. Alginate hydrogels were prepared based on a protocol by 
Jang et al. [32]. Briefly, a final concentration of 2 wt% sodium alginate was dissolved in 
PBS/media, followed by addition of calcium carbonate powder to the solution in a final 
molarity of 144 mM. This solution was thoroughly mixed through vortexing and sonicating. 
Another solution of GdL in the same corresponding solvent was prepared, with a CaCO3 to GdL 
molar ratio of 0.5 in order to keep the pH neutral. HeLa cells in a final concentration of 1x107 
cells/ml were added to the alginate/CaCO3 solution. The GdL solution was then added to this 
and rapidly mixed, then added to dishes for incubation. In later experiments which introduced 
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peptide-polymer compound to the gels, Tyr5-PEO6k-Tyr5 was mixed into the GdL solution, and 
then added to the rest of the mix as the protocol states.  
 
7.3 Results and discussion 
The secondary structure of the compounds was investigated using CD and FTIR. As with 
previous chapters, the temperature effect on secondary structure was also performed using 
temperature-dependent CD. The results are shown in figure 1. There are β-sheet features seen 
in the Tyr5-PEO6k-Tyr5 at native pH, shown in figure 1c, due to the minimum at 218 nm, and 
the maximum near 200 nm [33, 34]. The extra positive peak at 228 nm has previously been 
seen with a similar compound, Tyr2-PEO1.5k-Tyr2 [17], as well as another compound 
containing dityrosine residues [35], and is attributed to tyrosine residue absorption. The 
adjacent spectra of Tyr5-PEO6k-Tyr5 at pH 12 (figure 1d) shows a similar shape to the one at 
native pH, but with lower molar ellipticity values, which points to a reduction in secondary 
structure formation. The change in pH also leads to a red-shift in peaks, with the 200 nm 
positive peak shifting to 211 nm, and the 228 nm peak shifting to 241 nm. This change has 
previously been described [36], and is attributed to the formation of the phenoxide form of 
tyrosine at high pH, as opposed to the carboxyl-end group protonated/special position of 
tyrosine also previously described elsewhere [37]. Red-shifted β-sheet formation can also 
been seen with the Tyr5-PEO2k-Tyr5 sample with the minimum at 220 nm and maximum at 244 
nm. The same is true for Tyr3-PAla-Tyr3 which has a minimum at 226 nm, however the 
maximum is reduced, presumably due to overwhelming contribution from the alanine repeats. 
This spectrum is the only one which changes with temperature, with a progressive reduction in 
molar ellipticity, showing a reduction in self-assembled structure.  
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The four samples/conditions were then investigated through FTIR. All of the samples at all 
conditions show peaks in the 1500 cm-1 range, the amide II’ region, and show NH2 
deformations caused by the tyrosine residues. The amide I’ region reveals the self-assembly 
properties of the samples. The 1623 cm-1 peak seen with the Tyr3-PAla-Tyr3 spectrum has been 
correlated to formation of β-sheets [38], specifically for another alanine-rich peptide [39]. β-
sheets were also shown with Tyr5-PEO2k-Tyr5 through the 1635 cm-1 peak [38, 40]. The Tyr5-
PEO6k-Tyr5 at both pHs tested did not reveal peaks in this area despite the observation of β-
sheets in the CD data. This is believed to be due to the overwhelming absorption of the longer 
Figure 1 Temperature-dependent CD spectra of each sample at 0.1 wt% and pH 12 unless 
stated. a) Tyr3-PAla-Tyr3, b) Tyr5-PEO2k-Tyr5, c) Tyr5-PEO6k-Tyr5 at native pH = 5.69, d) 
Tyr5-PEO6k-Tyr5. 
a b
c d
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PEO chain. The largest peak, seen with all samples/conditions, is at around 3400 cm-1 which 
has been discussed in the previous amphotericin B chapter [41], and is attributed to O-H 
stretch bonds, along with amine stretch [42]. The peak at 2930 cm-1, along with the peak at 
3400 cm-1, have previously been seen with PEO compounds, with the former peak being 
attributed to PEO –CH2 or poly(alanine) backbone –CH deformation [43]. Temperature-
dependent FTIR, as with CD, would have revealed more information, particularly with the PAla 
sample due to the changes already seen upon increase in temperature in the CD data. 
However, this line of experiments was unable to be undertaken due to constraints on sample 
quantity and time. 
 
 
 
 
 
 
 
 
 
 
 
From each solution condition, a stalk was produced in order to perform fiber XRD. It was found 
that Tyr5-PEO6k-Tyr5 at both native and pH 12 produced the same result, and so only the 
Figure 2 FTIR spectra for samples at 1 wt% and pH 12 unless stated.  
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native pH is shown for clarity. The results are shown in figure 3. The PAla sample gave peaks at 
7.49, 5.27, 4.36 and 3.71 Å. Other peptides with oligo-alanine components have also been 
shown to give similar peaks, caused by the tightly packed β-sheets [39, 44-46]. The 4.36 Å peak 
has been previously assigned to the spacing between β-strands, and 5.27 Å to β-sheet spacing. 
The XRD data from Tyr5-PEO6k-Tyr5 shows the most prominent parts of the spectrum through 
peaks at 4.69 and 3.83 Å. The former peak has previously been associated with β-sheet 
content in fibril formation and corresponds to spacing between the peptide backbone [40, 47]. 
The others in the spectrum are assigned to a high degree of crystallisation of PEO. The 
crystallisation of PEO has previously been investigated through the use of XRD with expected 
d-spacings mapped out [48]. These are 7.89, 5.11, 4.63, 3.94, 3.86, 3.81, 3.79/3.78 Å. The Tyr5-
PEO2k-Tyr5 sample does not have any peaks which can be assigned to β-sheet content. It does 
however have a large amorphous peak with small sharp peaks on top, which the broad peak 
can be assigned to semi-crystalline PEO. The shift is believed to be from the influence of the 
tyrosine end-caps. The differing levels of crystallinity in the PEO containing samples can be 
explained through previous studies into its influence and the influence of peptide end groups. 
The Hamley group has shown that PEO crystallisation is enhanced when a less actively fibril-
forming peptide is linked to the same PEO centre block [49, 50]. A fibrilliser was also used 
bonded to a range of differing molar mass PEO centre blocks [51], and along with the results 
seen here suggest that a molar mass of 2000 g mol-1 of PEO may be on the borderline for 
observation of crystallinity.  
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Figure 3 X-ray diffraction data obtained from stalks dried from 1 wt% solutions. Figure 
courtesy of I.W. Hamley. 
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Cryo-TEM images of the samples are shown in figure 5. Both Tyr3-PAla-Tyr3 and Tyr5-PEO2k-
Tyr5 (figures 6a and b) show similar short fibrillar structures. These are commonly seen with 
self-assembling compounds which have shown β-sheet formation, as revealed in the CD and 
FTIR results. Tyr5-PEO6k-Tyr5 (figure 6c) on the other hand shows straight fibrils estimated to 
Figure 4 Corresponding 2D images of the X-ray diffraction data obtained from stalks dried from 1 
wt% solutions of a) Tyr5-PEO6k-Tyr5, b) Tyr5-PEO2k-Tyr5, and c) Tyr3-PAla-Tyr3. 
a b
c 
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have a diameter of 5 nm interspersed with much shorter, spherical-like structures. These very 
straight short fibrils are likely an influence of the longer PEO chain, based on observations of 
similar structures in previous work by the Hamley group involving other hydrophobic residues 
(phenyl alanine) attached to 5k units long PEO polymers [52]. By contrast, when shorter PEO 
blocks (up to 1800 g mol-1 tested [53]) are present, worm-like micelles, like those seen with 
Tyr5-PEO2k-Tyr5, are common [53].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c 
Figure 5 Representative cryo-TEM images of 1 wt% solutions at pH 12 unless otherwise 
stated of a) Tyr3-PAla-Tyr3, b) Tyr5-PEO2k-Tyr5, and c) Tyr5-PEO6k-Tyr5 at native pH. 
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SAXS data was collected (shown in figure 6) of Tyr5-PEO2k-Tyr5 and Tyr5-PEO6k-Tyr5. The 
structures observed in the cryo-TEM images were used as an input to constrain the form 
factor fitting of the structural parameters. Due to time restraints, Tyr3-PAla-Tyr3 wasn’t able to 
be done. Both of the samples were fitted to a cylindrical core-shell form factor, with specific 
parameters listed in table 1. The radius of the structures was found to be 1.03 nm for the Tyr5-
PEO2k-Tyr5 sample, and 2.28 nm for Tyr5-PEO6k-Tyr5, with the latter correlating well with the 
estimated diameter from the cryo-TEM images of 5 nm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 SAXS data obtained for 1 wt% solutions of a) Tyr5-PEO2k-Tyr5, and b) Tyr5-PEO6k-
Tyr5. Black squares show data, red line shows form factor fitting.  
a b 
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Sample N σ/nm R/nm ΔR/nm L/nm η(core) η(shell) η(solv) BG 
PEO2k 0.06 2.48 1.03 1.92 50 1.6 x 10-5 7.1 x 10-4 2.4 x 10-4 1.3 x 10-4 
PEO6k 0.015 2.66 2.28 2.20 50 4.1 x 10-4 1.7 x 10-3 1.0 x 10-4 3.0 x 10-4 
 
 
 
N = scaling factor 
σ = Gaussian polydispersity parameter 
R = cylinder radius 
ΔR = shell thickness 
L = length of cylinder (fixed value) 
η(core) = scattering length density of core 
η(shell) = scattering length density of shell 
η(solv) = scattering length density of solvent 
BG = background (fixed value) 
 
The samples were tested to determine whether they were able to form a gel by dissolving high 
weight % of the compounds. It was found that Tyr3-PAla-Tyr3 was unable to dissolve at higher 
concentrations, and Tyr5-PEO2k-Tyr5 and Tyr5-PEO6k-Tyr5 did not form a gel up to 
concentrations of 20 wt%. Rheological experiments on Tyr5-PEO6k-Tyr5 were performed by V. 
Castelletto, giving results indicating a largely fluid-like consistency. These are described in 
more detail in the published paper [30].  
Another objective with the compounds was to introduce them into cell cultures to determine 
their effects on cells. This was proposed due to the known functions of tyrosine in cell 
signalling and enzyme-responsiveness, described in more detail in the introduction. Another 
Table 1 Parameters for SAXS fitting form factor models using SASfit software. Form factor was 
cylindrical shell for both samples. 
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reason was PEO spacers, when linked to peptides, having shown to improve stability and 
circulation time, with applications including gene delivery [54] and cell signalling [55]. 
Therefore the two combined into one molecule posed an interesting compound to investigate 
their effects in cell culture. Due to the lack of gel formation by the three telechelic 
compounds, even at higher concentration, integration of them into an alginate-based hydrogel 
was proposed. The suitability of alginate gels being used for this purpose was described in 
more detail in the introduction. An already established protocol by Jang et al [32] was used as 
the basis for the alginate gel experiments, which manipulated cross-linking through addition of 
CaCO3 to sodium alginate, with GdL added to maintain neutral pH. This protocol was tested 
multiple times before introducing the polymer/peptide conjugates. During attempts to 
prepare the hydrogels and test out this protocol however, the pH was found to be around 
6.09, rather than neutral. This was understood to be unsuitable for cell culture experiments. 
The concentration of GdL used was then adjusted, which did lead to a more favourable pH, but 
also a much more fluid gel not suitable for the intended purpose. However, as the protocol 
[32] had been shown to be suitable for cell culturing previously, despite the observed pH being 
low, by a number of different groups [56, 57], this protocol was taken forward and used in 
further experiments. 
Assays, initially investigating the gels with no added polymer/peptide compound, were 
performed to determine the state and positioning of the cells with NucBlue staining, which 
binds to DNA and which stains nuclei. Imaging of cells in the gel in general proved to be 
difficult, due in part to the different planes of cells throughout the gel. Comparisons between 
a control (cells grown in media without gel present), gel made up in PBS, and gel made up in 
media after being left for 24 hours are shown in figure 7. The figures show a clear difference in 
cell confluence between the control in media, and the two gel samples, with the two samples 
leading to a much lower cell count versus the control. There is also a difference between the 
two gels, with PBS having a larger number cell count than the media gel.  
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After this relatively successful result, the alginate gel made up in PBS was chosen to be used in 
subsequent experiments. In order to conserve compound stock, only one of the peptide-
polymer conjugates was tested initially. Tyr5-PEO6k-Tyr5 was chosen and introduced into the 
PBS gel in the next portion of experiments along with cells at a final concentration of 1 wt%. 
The results are shown in figure 8 with a control of cells in media compared with cells in gel 
with and without Tyr5-PEO6k-Tyr5. The results show an aggregation of cells in both of the gel 
samples, compared with the confluence of cells seen in the control sample. However, the 
Figure 7 Cells incubated for 24 hours, then with NucBlue staining added. a) As a control, b) 
with PBS-based hydrogel, c) media-based hydrogel. 
a b
c 
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compound caused the gel to become lumpy and fluid when compared with the PBS gel 
without the compound, shown in the photographs of figure 9. Due to time constraints and lack 
of polymer/peptide samples, this study had to be left incomplete. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Cells incubated for 24 hours, then with ActinGreen staining added. Images 
taken 24 hours after gels added/not added. a) is a control, b) with PBS-based hydrogel, 
c) PBS-based hydrogel + 1 wt% Tyr5-PEO6k-Tyr5. 
a b 
c 
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In this chapter, the self-assembling properties of three different custom-synthesised triblock 
copolymers consisting of oligotyrosine end-caps and hydrophilic centre blocks were 
investigated. All three were shown to form fibrils, and the influence of tyrosine on self-
assembly was shown by the presence of even a short sequence containing only three tyrosines 
causing the formation of fibrils. There are some interesting observations of the differences 
between the three compounds. The polyalanine sample was shown to form very tightly-
packed β-sheets when compared with the PEO samples. During early sample preparation it 
was found that the Tyr5-PEO6k-Tyr5 sample, in contrast to the Tyr5-PEO2k-Tyr5 sample, did not 
Figure 9 Photographs of a) gel, and b) gel + 1 wt% Tyr5-PEO6k-Tyr5 
a 
b 
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need water alkalised to pH 12 in order for it to dissolve. The Tyr5-PEO6k-Tyr5 sample also 
formed incredibly straight fibers, in contrast to the more worm-like fibers of Tyr5-PEO2k-Tyr5, 
and exhibited PEO crystallinity unlike the semi-crystallinity observed for Tyr5-PEO2k-Tyr5. 
Unfortunately due to time constraints, the cytocompatibility of the compounds was not able 
to be investigated. This remains an interesting area for research owing to the role tyrosine 
plays in affecting cellular signalling etc., and the added effects PEO polymers bound to 
peptides can have, described in the introduction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 157 
 
7.4 References 
 
[1]  K. Heredia and H. Maynard, "Synthesis of protein-polymer conjugates," Organic & 
Biomolecular Chemistry, vol. 5, no. 1, pp. 45-53, 2007.  
[2]  L. Canalle, D. Lowik and J. van Hest, "Polypeptide–polymer bioconjugates," Chemical 
Society Reviews, vol. 39, pp. 329-353, 2010.  
[3]  P. Calceti and F. Veronese, "Pharmacokinetic and biodistribution properties of 
poly(ethylene glycol)-protein conjugates," Advanced Drug Delivery Reviews, vol. 55, no. 
10, pp. 1261-1277, 2003.  
[4]  A. Rosler, G. Vandermeulen and H. Klok, "Advanced drug delivery devices via self-
assembly of amphiphilic block copolymers," Advanced Drug Delivery Reviews, vol. 53, no. 
1, pp. 95-108, 2001.  
[5]  J. Nicolas, G. Mantovani and D. Haddleton, "Living radical polymerization as a tool for the 
synthesis of polymer-protein/peptide bioconjugates," Macromolecular Rapid 
Communications, vol. 28, no. 10, pp. 1083-1111, 2007.  
[6]  P. Bailon and W. Berthold, "Polyethylene glycol-conjugated pharmaceutical proteins," 
Pharmaceutical Science & Technology Today, vol. 1, no. 8, pp. 352-356, 1998.  
[7]  W. Wimley and S. White, "Experimentally determined hydrophobicity scale for proteins at 
membrane interfaces," Nature Structural Biology, vol. 3, no. 10, pp. 842-848, 1996.  
[8]  T. Hessa, H. Kim, K. Bihlmaier, C. Lundin, J. Boekel, H. Andersson, I. Nilsson, S. White and 
G. von Heijne, "Recognition of transmembrane helices by the endoplasmic reticulum 
translocon," Nature, vol. 433, no. 7024, pp. 377-381, 2005.  
[9]  J. Kyte and R. Doolittle, "A simple method for displaying the hydropathic character of a 
protein," Journal of Molecular Biology, vol. 157, no. 1, pp. 105-132, 1982.  
[10]  C. Moon and K. Fleming, "Side-chain hydrophobicity scale derived from transmembrane 
protein folding into lipid bilayers," Proceedings of the National Academy of Sciences of the 
United States of America, vol. 108, no. 25, pp. 10174-10177, 2011.  
[11]  S. White and W. Wimley, "Membrane protein folding and stability: physical principles," 
Annual Review of Biophysics and Biomolecular Structures, vol. 28, pp. 319-365, 1999.  
[12]  K. Taylor and H. Naser-El-Din, "Water-soluble hydrophobically associating polymers for 
improved oil recovery: A literature review," Journal of Petroleum Science and Engineering, 
vol. 19, no. 3-4, pp. 265-280, 1998.  
[13]  C. Chassenieux, T. Nicolai and L. Benyahia, "Rheology of associative polymer solutions," 
Current Opinion in Colloid & Interface Science, vol. 16, no. 1, pp. 18-26, 2011.  
[14]  E. Larraneta and J. Isasi, "Phase behavior of reverse poloxamers and poloxamines in 
water," Langmuir, vol. 29, no. 4, pp. 1045-1053, 2013.  
 158 
 
[15]  A. McNaught and A. Wilkinson, "IUPAC," in Compendium of Chemical Terminology, 2nd 
ed. (the "Gold Book"), Oxford, Blackwell Scientific Publications, 1997.  
[16]  I. Hamley, Block Copolymers in Solution, Chichester: Wiley, 2005.  
[17]  I. Hamley, G. Cheng and V. Castelletto, "A thermoresponsive hydrogel based on telechelic 
PEG end-capped with hydrophobic dipeptides," Macromolecular Bioscience, vol. 11, no. 8, 
pp. 1068-1078, 2011.  
[18]  K. Julich-Gruner, A. Neffe and A. Lendlein, "Synthesis and characterization of 
oligo(ethylene glycol)s functionalized with desaminotyrosine or desaminotyrosyltyrosine," 
Journal of Applied Biomaterials & Functional Materials, vol. 10, no. 3, pp. 170-176, 2012.  
[19]  S. Hua, Y. Li, Y. Liu, W. Xiao, C. Li, F. Huang, X. Zhang and R. Zhuo, "Self-assembled micelles 
based on PEG-polypeptide hybrid copolymers for drug delivery," Macromolecular Rapid 
Communications, vol. 31, no. 1, pp. 81-86, 2010.  
[20]  D. Adams and P. Topham, "Peptide conjugate hydrogelators," Soft Matter, vol. 6, pp. 
3707-3721, 2010.  
[21]  J. Shu, B. Panganiban and T. Xu, "Peptide-polymer conjugates: from fundamental science 
to application," Annual Review of Physical Chemistry, vol. 64, pp. 631-657, 2013.  
[22]  A. Sodhi, D. Campbell and P. Topham, "Polymer-peptide conjugate hydrogels; towards 
controlled drug delivery," Chiang Mai Journal of Science, vol. 39, no. 3, pp. 351-372, 2012.  
[23]  M. Lutolf and J. Hubbell, "Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering," Nature Biotechnology, vol. 
23, no. 1, pp. 47-55, 2005.  
[24]  Y. Nagai, L. Unsworth, S. Koutsopoulos and S. Zhang, "Slow release of molecules in self-
assembling peptide nanofiber scaffold," Journal of Controlled Release, vol. 115, no. 1, pp. 
18-25, 2006.  
[25]  A. Augst, H. Kong and D. Mooney, "Alginate hydrogels as biomaterials," Macromolecular 
Bioscience, vol. 6, no. 8, pp. 623-633, 2006.  
[26]  K. Lee and D. Mooney, "Alginate: properties and biomedical applications," Progress in 
Polymer Science, vol. 37, no. 1, pp. 106-126, 2012.  
[27]  T. Andersen, P. Auk-Emblem and M. Dornish, "3D Cell Culture in Alginate Hydrogels," 
Microarrays, vol. 4, no. 2, pp. 133-161, 2015.  
[28]  G. Palazzolo, N. Broguiere, O. Cenciarelli, H. Dermutz and M. Zenobi-Wong, "Ultrasoft 
alginate hydrogels support long-term three-dimensional functional neuronal networks," 
Tissue Engineering. Part A., vol. 21, no. 15-16, pp. 2177-2185, 2015.  
[29]  M. Lemmon and J. Schlessinger, "Cell signaling by receptor tyrosine kinases," Cell, vol. 
141, no. 7, pp. 1117-1134, 2010.  
[30]  S. Kirkham, V. Castelletto, I. Hamley, M. Reza, J. Ruokolainen, D. Hermida-Merino, P. 
Bilalis and H. Iatrou, "Self-Assembly of Telechelic Tyrosine End-Capped PEO and 
 159 
 
Poly(alanine) Polymers in Aqueous Solution," Biomacromolecules, vol. 17, no. 3, pp. 1186-
1197, 2016.  
[31]  T. Creighton, Proteins: Structures and Molecular Properties, New York: W.H.Freeman, 
1993.  
[32]  J. Jang, Y. Seol, H. Kim, J. Kundu, S. Kim and D. Cho, "Effects of alginate hydrogel cross-
linking density on mechanical and biological behaviors for tissue engineering," Journal of 
the Mechanical Behaviour of Biomedical Materials, vol. 37, pp. 69-77, 2014.  
[33]  C. Toniolo, F. Formaggio and R. Woody, "Electronic Circular Dichroism of Peptides," in 
Comprehensive Chiroptical Spectroscopy: Applications in Stereochemical Analysis of 
Synthetic Compounds, Natural Products, and Biomolecules, Volume 2, New York, Wiley-
Blackwell, 2012.  
[34]  B. Norden, A. Rodger and T. Dafforn, Linear Dichroism and Circular Dichroism: A Textbook 
on Polarized-Light Spectroscopy, Royal Society of Chemistry, 2010.  
[35]  I. Hamley, V. Castelletto, C. Moulton, D. Myatt, G. Siligardi, C. Oliveira, J. Pederson, I. 
Abutbul and D. Danino, "Self-assembly of a modified amyloid peptide fragment: pH-
responsiveness and nematic phase formation," Macromolecular Bioscience, vol. 10, no. 1, 
pp. 40-48, 2010.  
[36]  G. Siligardi, M. Campbell, W. Gibbons and A. Drake, "Conformational analysis of the 
melanin-concentrating hormone core by circular dichroic spectroscopy. Disulphide bridge 
and tyrosine contributions," European Journal of Biochemistry, vol. 206, no. 1, pp. 23-29, 
1992.  
[37]  D. Brown, M. Campbell, R. Kinsman, P. White, C. Moss, D. Osguthorpe, P. Paul and B. 
Baker, "Melanin-concentrating hormone: a structural and conformational study based on 
synthesis, biological activity, high-field NMR, and molecular modeling techniques," 
Biopolymers, vol. 29, no. 3, pp. 609-622, 1990.  
[38]  A. Adochitei and G. Drochioiu, "Rapid characterization of peptide secondary structure by 
FTIR spectroscopy," Academia Romana, vol. 56, no. 8, pp. 783-791, 2011.  
[39]  I. Hamley, A. Dehsorkhi, V. Castelletto, J. Seitsonen, J. Ruokolainen and H. Iatrou, "Self-
assembly of a model amphiphilic oligopeptide incorporating an arginine headgroup," Soft 
Matter, vol. 9, no. 19, pp. 4794-4801, 2013.  
[40]  I. Hamley, "Peptide fibrillisation," Angewandte Chemie, vol. 46, no. 43, pp. 8128-8147, 
2007.  
[41]  I. Hamley, S. Kirkham, R. Kowalczyk, V. Castelletto, M. Reza and J. Ruokolainen, "Self-
assembly of the anti-fungal polyene amphotericin B into giant helically-twisted 
nanotapes," Chemical Communications, vol. 51, no. 100, pp. 17680-17683, 2015.  
[42]  L. Bellamy, The Infrared Spectra of Complex Molecules, London: Springer Netherlands, 
1980.  
[43]  A. Dehsorkhi, V. Castelletto, I. Hamley and P. Harris, "Multiple hydrogen bonds induce 
formation of nanoparticles with internal microemulsion structure by an amphiphilic 
 160 
 
copolymer," Soft Matter, vol. 7, no. 21, pp. 10116-10121, 2011.  
[44]  I. Hamley, A. Dehsorkhi and V. Castelletto, "Self-assembled arginine-coated peptide 
nanosheets in water," Chemical Communications, vol. 49, no. 18, pp. 1850-1852, 2013.  
[45]  D. Middleton, J. Madine, V. Castelletto and I. Hamley, "Insights into the Molecular 
Architecture of a Peptide Nanotube Using FTIR and Solid-State NMR Spectroscopic 
Measurements on an Aligned Sample," Angewandte Chemie, vol. 52, no. 40, pp. 10537-
10540, 2013.  
[46]  I. Hamley, S. Kirkham, A. Dehsorkhi and V. Castelletto, "Self-assembly of a model peptide 
incorporating a hexa-histidine sequence attached to an oligo-alanine sequence, and 
binding to gold NTA/nickel nanoparticles," Biomacromolecules, vol. 15, no. 9, pp. 3412-
3420, 2014.  
[47]  L. Serpell, "Alzheimer's amyloid fibrils: structure and assembly," Biochimica et Biophysica 
Acta, vol. 1502, no. 1, pp. 16-30, 2000.  
[48]  Y. Takahashi and H. Tadokoro, "Structural studies of polyethers, (-(CH2)m-O-)n.X. Crystal 
structure of poly(ethylene oxide)," Macromolecules, vol. 6, pp. 672-675, 1973.  
[49]  I. Hamley and M. Krysmann, "Effect of PEG crystallization on the self-assembly of 
PEG/peptide copolymers containing amyloid peptide fragments," Langmuir, vol. 24, no. 
15, pp. 8210-8214, 2008.  
[50]  M. Krysmann, S. Funari, E. Canetta and I. Hamley, "The effect of PEG crystallization on the 
morphology of PEG/peptide block copolymers containing amyloid beta-petide 
fragments," Macromolecular Chemistry and Physics, vol. 209, no. 9, pp. 883-889, 2008.  
[51]  V. Castelletto, G. Newby, Z. Zhu, I. Hamley and L. Noirez, "Self-assembly of PEGylated 
peptide conjugates containing a modified amyloid beta-peptide fragment," Langmuir, vol. 
26, no. 12, pp. 9986-9996, 2010.  
[52]  V. Castelletto and I. Hamley, "Self assembly of a model amphiphilic phenylalanine 
peptide/polyethylene glycol block copolymer in aqueous solution," Biophysical Chemistry, 
vol. 141, no. 2-3, pp. 169-174, 2009.  
[53]  N. Tzokova, C. Fernyhought, M. Butler, S. Armes, A. Ryan, P. Topham and D. Adams, "The 
effect of PEO length on the self-assembly of poly(ethylene oxide)−tetrapeptide conjugates 
prepared by “click” chemistry," Langmuir, vol. 25, no. 18, pp. 11082-11089, 2009.  
[54]  M. Pilkington-Miksa, S. Sarkar, M. Writer, S. Barker, P. Shamlou, S. Hart, H. Hailes and A. 
Tabor, "Synthesis of bifunctional integrin-binding peptides containing PEG spacers of 
defined length for non-viral gene delivery," European Journal of Organic Chemistry, vol. 
2008, no. 17, pp. 2900-2914, 2008.  
[55]  F. Dekker, N. de Mol, J. van Ameijde, M. Fischer, R. Ruijtenbeek, F. Redegeld and R. 
Liskamp, "Replacement of the intervening amino acid sequence of a Syk-binding 
diphosphopeptide by a nonpeptide spacer with preservation of high affinity," 
Chembiochem, vol. 3, no. 2-3, pp. 238-242, 2002.  
 161 
 
[56]  A. Travan, F. Scognamiglio, M. Borgogna, E. Marsich, I. Donati, L. Tarusha, M. Grassi and S. 
Paoletti, "Hyaluronan delivery by polymer demixing in polysaccharide-based hydrogels 
and membranes for biomedical applications," Carbohydrate Polymers, vol. 150, no. 5, pp. 
408-418, 2016.  
[57]  F. You, X. Wu, N. Zhu, M. Lei, B. Eames and X. Chen, "3D printing of porous cell-laden 
hydrogel constructs for potential applications in cartilage tissue engineering," ACS 
Biomaterials Science and Engineering, vol. 2, no. 7, pp. 1200-1210, 2016.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 162 
 
Chapter 8 - General conclusions and future work 
 
Throughout these six chapters, the self-assembly properties of a range of compounds has 
been investigated, including commercially available antimicrobial and antifungal compounds, 
TLR-agonists, and novel, custom-synthesised peptide-based molecules.  
In chapter 2, three different TLR agonist lipopeptides were investigated consisting of a peptide 
sequence, CSK4, with one, two, or three attached palmitoyl chains. It was found that the self-
assembly properties were similar when one and two lipid chains were attached; showing 
disordered secondary structure which wasn’t modified by temperature change, and spherical 
micelle formation. This contrasted with the three lipid chain Pam3CSK4, which showed β-sheet 
secondary structure partially reversibly transitioning into disordered conformation upon 
heating, along with worm-like micelle formation.  Differences between the three were also 
noted in terms of the cac values, which decreased with increasing lipid chain number. These 
differences in self-assembly based on number of attached lipid chains may relate to 
bioactivity. 
Future work could investigate whether there is any interaction of the self-assembled 
structures with the TLRs, and the mechanism by which this occurs if so. This would likely 
involve a ligand binding assay to firstly detect the quantity of binding at the concentration 
used in this work at which these nanostructures form. When the PamnCSK4 are bound to the 
TLRs, microscopy using labelling techniques may be able to shed more light on the nature of 
the interaction of the nanostructures with the receptors, if indeed there is any.  
The work in chapter 2 influenced the research in chapter 3, which investigated the self-
assembly and effect the attached lipid chains had on another TLR agonist; MALP-2. Here, the 
differences between the self-assembly of MALP-2 and its constituent peptide 
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(GNNDESNISFKEK) were investigated. There were notable differences in cryo-TEM images, 
where twisted tapes were seen with the peptide, contrasted with more organised raft-like 
structures of MALP-2, which appeared to be composed of laterally bound tape-like fibers. 
These raft-like structures are interesting as they have not been reported before for 
lipopeptides as far as we are aware. These results clearly show the strong influence lipid 
chains are able to have on self-assembly, particularly in the case of MALP-2.  
One of the questions for the future of this specific research would be to discover the kinetics 
and mechanisms of the formation of the raft-like structures. The samples used in cryo-TEM 
experimentation in the chapter were left for several days before being imaged. Therefore 
imaging at various time points starting from when the compound was first dissolved may give 
insight into the structure formation steps. It would also be interesting to determine whether 
the higher concentrations used in this study would affect the bioactivity of the compound, and 
if so, in what way. Relevant bioassays have already been used to determine the bioactivity at 
lower concentrations [1, 2]. 
Chapter 4 consisted of an investigation into a peptide conjugate comprising a dileucine motif 
attached to a bulky aromatic fluorophore; fluorescein isothiocyanate (FITC). The 
determination of the cac of the compound was interesting as it was shown to self-assemble 
above a cac using its own self-fluorescing properties, until a point at which self-quenching 
occurs. This was believed to be due to the formation of large extended nanosheets, seen 
through cryo-TEM images, which had not previously been observed for this group of 
compound. The secondary structure data showed apparent inconsistencies, with FTIR data 
showing potential β-sheet formation which wasn’t seen in the CD data. This could however be 
explained through formation of the large sheets, or UV absorbance effects. Experimentation of 
the compound incubated in cell culture showed that it was not cytotoxic, and was readily 
taken up into cells when compared with FITC on its own. This showed the ability of the 
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dileucine motif to enable transport into the cells. Further experimentation showed specific 
localisation in peri-nuclear regions. The mechanism by which FITC-LL is uptaken poses an 
interesting question for future research, as the dilecuine motif seems too short to relate to 
any transporter sequence.  
In chapter 5, the self-assembling properties of a commercial antifungal drug, amphotericin B, 
were explored. A time-dependent change in secondary structure was shown to occur through 
a change in CD signal over a 24 hour time period. A novel CD peak was seen at 326 nm in a 
spectrum not previously observed for this compound. As the concentration used was over the 
experimentally determined cac, this leads to the belief that aggregated forms of amphotericin 
B evolve over time to form a different aggregated conformation. Fluorescence-lifetime 
imaging microscopy (FLIM) experimentation disputed previous reports, including by the 
Starzyk group [3], that amphotericin B can be present in two different dimer forms; parallel 
and antiparallel based on observed differing lifetimes. In their work, this was shown through 
the use of different solvents. The FLIM data in this chapter showed that different lifetimes 
could be seen by just changing the excitation wavelength. As this was only preliminary data, 
full conclusions could not be drawn, but it poses questions for future work. A model of the 
twisted tapes observed for amphotericin B in pH 11/12 solutions has been tentatively 
proposed by I.W. Hamley in the published paper [4]. A more in-depth study of these novel 
nanostructures would be interesting for future work, paired with computer simulations, to 
further characterise them. 
Chapter 6 described an investigation into the self-assembly of another commercially available 
drug; daptomycin, a lipopeptide used against infection by gram-positive bacteria. It had been 
believed that calcium ions are required in order for self-assembly to occur, which is linked to 
the mechanism of action of the drug. Cac measurements showed that the compound 
aggregated at the same concentration whether in the presence of calcium ions or not. Cryo-
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TEM images also showed the formation of spherical micelles in the presence and absence of 
calcium ions. Secondary structure studies were performed, with CD showing no systematic 
differences in spectra between the different sample conditions. FTIR showed similarities in the 
1250-2000 cm-1 region, but differences in peak intensity relating to –OH stretch vibrations, 
potentially explained through increased H-bond stabilisation in the presence of higher calcium 
ions. These results together suggest that daptomycin self-assembly does not require the 
presence of calcium ions.  
The final chapter, chapter 7, concerned three different custom-synthesised compounds 
containing a repeating hydrophilic centre block (either PEO or poly alanine), with short 
hydrophobic tyrosine end-caps. The self-assembly of the compounds was investigated using 
the methods employed in the other chapters. All three compounds (Tyr3-PAla-Tyr3, Tyr5-
PEO2k-Tyr5 and Tyr5-PEO6k-Tyr5) were shown to form fibrils through cryo-TEM, although the 
Tyr5-PEO6k-Tyr5 sample differed from the other two, forming very straight fibers compared 
with worm-like micelles. All samples showed some β-sheet formation, and in the case of the 
poly alanine compound, very tightly-packed β-sheets. These tightly packed sheets were also 
shown through XRD, which showed little or no PEO crystallinity in the case of the PEO2k 
sample, and a high degree of crystallinity in the PEO6k sample. In addition to the self-
assembling properties, some preliminary experiments were also conducted into the 
cytocompatibility of the compounds. As the compounds were shown to be unable to form into 
gels at high concentrations, they were incorporated into an alginate-based hydrogel. Due to 
time constraints and lack of compound, these experiments remained incomplete and 
inconclusive.  
Future work would involve continuing on with cytocompatibility tests of the compounds when 
introduced into alginate gels, or potentially other gels. The addition of adhesion motifs (RGD) 
in order to increase the binding and growth of cells in the gel would alleviate some of the 
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difficulties experienced in the chapter. Tyrosine reactivity of the end caps of these compounds 
was not a focus of this work, but could pose questions for future studies. Tyrosine residues can 
for example be induced through kinases, which are important reactions in cell signalling. It 
would also be interesting to attempt to induce gelation of the compounds through alteration 
of pH.  
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